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1. Introduction 
1.1 Introduction to urine 
Urine is a liquid by-product of the blood that is secreted via the kidneys. It consists of 95 % 
water, whereas the remaining constitutes salts, amino acids and broken down blood 
pigments. Kidneys usually maintain plasma osmolarity by regulating water excretion. A large 
volume of plasma (350-400 ml/100 g of tissue per min) is filtered by the kidneys. The rate at 
which the plasma is filtered is known as the glomerular filtration rate, which is normally 125 
ml/minute or 180 liters/day. After filtration most components in the filtrate such as water, 
glucose, amino acids, and salts are reabsorbed back. Then, the urine formed is passed 
through ureter to bladder and finally flow out through urethra (Figure 1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Urinary systems.  
Plasma is filtered by the glomeruli to form “primitive urine”. However, 99% of this primitive 
urine is reabsorbed by the renal tubule. The remainder “final urine” exist the kidney via the 
ureter into the bladder. The picture obtained from (Decramer et al., 2008) 
Normally, protein concentration in urine of healthy donors is very low (less than 100 mg/liter 
when urine output is 1.5 liters/day), whereas protein excretion is less than 150 mg/day. 
Excretion of more than 150 mg/day proteins are defined as proteinuria and are indicative of 
glomerular or reabsorption dysfunction. 
 
1.2 Sources of urinary proteins 
It is believed that proteins with a molecular weight of <15 kDa pass freely in the glomeruli 
whereas proteins up to 60 kDa can pass through but not freely. In addition, proteins larger 
than 60 kDa do not pass through the kidneys (Schenk et al., 2008). However, large 
primitive urine
= reabsorption
final urine
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molecular weight proteins have been detected in urine. Mass spectrometry analysis revealed 
presence of extracellular proteins, plasma membrane proteins, and lysosomal proteins such 
as LAMP-1, LAMP-2 and LAMP-3 in the urine (Adachi et al., 2006). They suggested that 
there may be specific transport pathways for plasma membrane proteins and lysosome 
proteins. Additional proteomics studies have revealed many extracellular and plasma 
membrane protein of >60 kDa proteins in urine (Jia et al., 2009). They suggested that 
enrichment of these proteins in urine might be a regulatory filtration mechanism.   
However, the source of proteins in urine under normal conditions were grouped into three 
categorize (Pisitkun et al., 2006). 
1. Soluble proteins derived from largely glomerular filtration 
2. Soluble proteins secreted/cleaved from the epithelial layer of glomerular membrane 
3. Proteins attached with solid phase compartment from glomelular membrane 
In another study of urine collected from healthy donors indicated that, 49% were soluble, 
48% were contained in small cell membrane fragments, and the remaining 3% was in 
exosomes Table 1 (Barratt and Topham, 2007). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Sources of urinary proteins. 
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1.2.1 Soluble proteins derived from glomerular filtration  
Most soluble proteins in urine are derived largely from glomerular filtration. The glomerular 
filter effectively retards passage of high molecular weight proteins. However, even with very 
low sieving coefficients, proteins that are abundant in the blood plasma such as albumin and 
various globulins can pass the glomerular filter in substantial amounts to enter the lumen of 
the nephron. Most of the proteins and peptides that pass the glomerular filter are scavenged 
and proteolyzed in the proximal tubule by highly specialized apical uptake processes that 
involves receptor-like recognition of the polypeptides (Christensen and Birn, 2001; 
Christensen, 2002). Defect in the glomerular filtration increases the excretion of high 
molecular weight proteins. 
1.2.2 Soluble proteins cleaved from glomelular membrane 
These are membrane-bound proteins that are proteolycally cleaved from the epithelial cells 
of urinary tract for example Tamm-Horsfall glycoprotein (THP) also known as uromodulin. It 
is a glycoprotein with molecular weight of approximately 85 kDa (Serafini-Cessi et al., 1993). 
Uromodulin is the most abundant protein in urine of healthy donors. It is usually secreted by 
the thick ascending limb of Henle loop, a nephron segment downstream from the proximal 
tubule (Serafini-Cessi et al., 2003). 
1.2.3 Solid phase proteins 
Proteins in urine are also found in urine sediments. Urine sediments consist mainly of whole 
cells, cells debris, and leukocytes. They are normally secreted into the urine from all renal 
tract epithelial cells. Recently tiny vesicles called “exosomes” were discovered in normal 
urine (Pisitkun et al., 2004a). Exosomes usually contain vesicular membranes and 
intracellular components of the urinary system. They may also contain proteins that are 
altered in abundance or physical properties in association with various renal diseases. In 
addition sediment proteins can be components of small fragments of cell membranes that 
are delivered to the urinary space from urinary tract. These may be due to budding off parts 
of the outer cell membrane or apoptotic cells. 
1.3 Urine as a source of biomakers 
A biomaker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacologic responses to a 
therapeutic indication. Urine provides several advantages compared to serum or plasma and 
cerebrospinal fluid (CSF). 
It is noninvasive  
1. Easy to be obtained in large amounts. 
1 Introduction 
 16 
2. Proteins and peptides in urine are quite stable. 
3. The amount and composition of urinary proteome directly reflect changes in functions 
of the kidneys and the urogenonital tract. 
On the other hand use of urine has some disadvantages as follows: 
1. Urine contains low protein concentration and this varies between individual’s 
samples. 
2. In addition urine contains high levels of salts. 
3. Urine may contain bacteria from lower urogenital tract. In addition, storage at room 
temperature for more than 6 hours or at 4°C for more than 24 hours encourages more 
bacteria to grow. Therefore, addition of sodium azide or boric acid to prevent bacterial 
contamination and grow is highly recommended.   
4. Some proteins precipitate down when urine is stored at 4°C and at -20°C and they 
are not easily redissolved. It is recommended that urine sample should be 
immediately frozen at –80°C after collection to avoid loss of proteins.  
 
The use of urinary biomarkers to diagnose disease is a long-standing practice. Ancient 
clinicians detected glucose in urine by tasting. In early times presence of albumin could be 
detected by the “foam test”. Today large scale proteomics profiling of normal human urine 
samples has revealed the presence of at least 1000 different proteins and peptides 
(Castagna et al., 2005; Jurgens et al., 2005; Oh et al., 2004a; Smith et al., 2007; Sun et al., 
2005; Pisitkun et al., 2004a). In this regard urine proteins offer a great potential in biomaker 
discovery of kidney and non-kidney diseases. For example decrease of Tamm-Horsfall 
protein concentration in urine has been found to be a good indicator of kidney stones (Ganter 
et al., 1999). In addition, urine proteins as cancer biomarker have been reported for prostate 
cancer (Theodorescu et al., 2008), and bladder cancer (Saito et al., 2005). Recently it was 
reported that CEACAM1 in urine can be used as a biomarker for bladder carcinoma (Tilki et 
al., 2009) indicating the presence of soluble CEACAM1 form in urine. 
 
1.4 Introduction to CEACAM family 
Carcinoembryonic antigen (CEA)-related cell adhesion molecules (CEACAMs) belong to the 
immunoglobulin (Ig) superfamily of cellular surface molecules. This gene family is located in 
the q13.1-2 region of human chromosome 19. To date, the human CEA gene family includes 
29 different genes and pseudogenes (Olsen et al., 1994). These are subdivided into the 
CEA-related cell-adhesion molecules (CEACAMs) and the pregnancy-specific glycoprotein 
(PSGs) as shown below (Figure 2). 
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 Figure 2: Schematic structure of the carcinoembryonic antigen (CEA) gene family.  
The letters A and B next to the domains represent the two IgC-like domains. A modified 
diagram from (Gray-Owen and Blumberg, 2006) 
 
They consist of one N-terminal variable like domain (IgV-like domain) followed by up to six 
domains homologous to the immunoglobulin constant region-type-2-like (IgC2-like) domains 
(Williams et al., 1988). The structure of the N-domain consists of a pair of β-sheets with nine 
β-strands (Williams et al., 1988). Another important structural feature of CEACAMs is that 
they are heavy glycosylated, generally more than half the receptor’s molecular weight 
consists of carbohydrates (Williams et al., 1988). However, the level of glycosylation may 
vary depending upon cell type. The N-liked glycans contain high mannose and complex type 
oligosaccharides like lactosaminoglycans (glycoconjugates containing Galβ1,4GlcNAc 
mofit/mofits) type 1 and type II, terminated by fucosl- and sialyl-residues (Odin et al., 1986).  
CEACAM1, CEACAM3, and CEACAM4, are anchored to the membrane by short or long 
cytoplasmic domains, whereas CEACAM5, CEACAM6, CEACAM7, and CEACAM8 are by a 
glycosyl phosphatidyl inositol (GPI) anchor. CEACAM5 was the first to be discovered among 
all CEACAMs. 
1.5 Expression of CEACAM5 
CEACAM5, also known as CEA was discovered as a tumor-associated antigen in human 
colorectal carcinoma (GOLD and FREEDMAN, 1965). Originally, CEACAM5 was considered 
an oncofetal protein that is re-expressed in adult tissues only during carcinogenesis. Later, it 
became evident that it is expressed both in embryonic and healthy adult tissue such as colon 
and pancreas (Albers et al., 1988; Frangsmyr et al., 1999). Normal expression of CEACAM5 
is restricted to the epithelial cells. It is expressed most abundantly on the apical surface of 
the gastrointestinal epithelium, but also on other mucosal epithelial cells of nasopharynx, 
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lung, urogenital tract and sweet glands (Thompson, 1995). Overexpression of CEACAM5 
has been shown to disturb the ordered tissue architecture of several colon carcinoma cell 
lines (Ilantzis et al., 2002). Furthermore, CEA levels in serum are elevated during the 
progression of various malignant diseases such as colon, breast or lung cancers. CEA 
serves as a clinical tumor maker and is of important prognostic relevance in the evaluation of 
progressive colon tumors, an increase of it in serum indicates recurrences and residual 
disease(Thomson et al., 1969). 
It is characterized by having seven extracellular Ig domains which includes an N-terminal 
domain. It has a molecular weight of approximately 180 kDa (Oikawa et al., 1987). 
1.6 Expression pattern of other CEACAM family members 
Similar to CEACAM5 several other members of the CEACAM family have been reported. 
CEACAM3 also known as CD66d has a molecular weight of approximately 35 kDa. It exists 
in two splice variants (CEACAM3L and CEACAM3S) with a long and a short cytoplasmic 
domain. It is solely expressed on human granulocytes (Nagel et al., 1993; Chen and 
Gotschlich, 1996).  
CEACAM4 also known as CGM-7, is uniquely expressed on primary human granulocytes 
(Kuroki et al., 1991). However, this is not clear because it has not to shown at protein level 
due to lack of monospecific antibody. 
CEACAM6 is alternatively known as CD66c and nonspecific cross-reacting antigen-50/90 
(NCA-50/90). It was referred as NCA-50/90 because in granulocytes it detected as having 50 
kDa and 90 kDa due to different glycosylation. CEACAM6 displays a fairly broad expression 
pattern, as it shares common sites of expression with CEACAM1. It is usually expressed in 
epithelia of different organs such as breast, salivary glands, pancreas, stomach, and sweat 
glands (Kodera et al., 1993; Metze et al., 1996; Scholzel et al., 2000b). However, no 
expression can be detected on the basolateral side of the gut epithelium (Hansson et al., 
1989; Frangsmyr et al., 1999). It is also expressed in granulocytes, monocytes, B and T 
lymphocytes (Scholzel et al., 2000b; Singer et al., 2002). Significant amount of soluble 
CEACAM6 has been detected in serum of patients with pancreatic, breast, colon, and 
hepatocellular carcinomas(Kuroki et al., 1999). 
CEACAM7 alternatively known as CGM2, has a molecular weight of approximately 45 kDa. It 
reveals an expression pattern similar to that of CEACAM5, although it is not found in 
granulocytes. CEACAM7 is expressed in the normal pancreatic and colon 
epithelium(Scholzel et al., 2000b). However, it is down regulated in colorectal tumors 
(Scholzel et al., 2000b). 
A glycosylphosphatidyl-inositol-(GPI)-anchored glycoprotein, CEACAM8 was identified in 
human neutrophils 20 years ago (Buchegger et al., 1984). It is alternatively known as, 
CD66b, CD67 and NCA-95. Furthermore, it has a molecular weight of 90 kDa. CEACAM8 is 
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recognized as granulocyte-specific marker, granulocyte activation marker and as marker in 
patients with rheumatoid arthritis (Torsteinsdottir et al., 1999; Zhao et al., 2004). It is solely 
expressed in the granulocytes lineage (Berling et al., 1990). Studies have suggested that 
CEACAM8 is present mainly in the secondary granules, tertiary granules, secretory vesicles 
and on the cell surface of granulocytes (Ducker and Skubitz, 1992; Kuroki et al., 1995; Feuk-
Lagerstedt et al., 1999). 
CEACAM1 appears to be phylogenetically most ancient member of the CEACAM family 
(Stanners et al., 1992; Thompson and Zimmermann, 1988). It has been suggested, that GPI-
linked CEA family members evolved from an ancestral CEACAM1-like gene by replication 
and mutation of a primordial transmembrane exon (Naghibalhossaini and Stanners, 2004; 
Stanners et al., 1992; Streydio et al., 1990). CEACAM1 was the focus of our study. 
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1.7 Discovery and structure of CEACAM1 
Carcinoembroyonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1), also known 
as biliary glycoprotein 1 (BGP1) and CD66a is a member of the CEA-gene family. It has a 
molecular weight of approximately 120 kDa. It was first described as CEA-cross–reacting 
antigen from human bile (Svenberg, 1976b). Like all other expressed CEA family members, 
CEACAM1 consists of an N-terminal immunoglobulin variable–region like (IgV-like) domain, 
followed by up to three immunoglobulin constant-region type-2-like (IgC2-like) domains. The 
N-terminal domain consists of 108 amino acids (aa), while the IgC-like domains are found in 
two variants, the A and B domains. The A-domains contain 92-93 aa, whereas B-domain 
comprise 85-86 aa. As most Ig folds, the IgC2 set domains are stabilized by a disulfide 
bridge formed between paired cystine residues. The CEACAM1 gene transcript is sliced into 
11 different isoforms, which differ with respects to the number of Ig-C-like domains and the 
length of the cytoplasmic domain (Figure 3). CEACAM1 with four extracellular 
immunoglobulin–like domains was named CEACAM1-4 which can either have a long or a 
short cytoplasmic tail. CEACAM1-4 with a long cytoplasmic tail is known as CEACAM1-4L 
whereas CEACAM1 with a short cytoplasmic tail is known as CEACAM1-4S. The other 
isoforms are CEACAM1-3L with long cytoplasmic tail and CEACAM1-3S with short 
cytoplasmic tail both lacking the second A-domain (Barnett et al., 1989). The other isoforms 
either lacks all IgC-like domains or contain some non-Ig-like regions (Barnett et al., 1993). 
Furthermore, they are poorly characterized in terms of function and expression pattern. It is 
important to note that all isoforms contain the N-domain, by which CEACAM1 mediateS 
homophilic binding by its non-glycosylated  β-pleated sheets (Stern et al., 2005; Watt et al., 
2001). 
The functional differences between the isoforms containing different numbers of extracellular 
domains remain unclear. However, the differential splicing of exons encoding the cytoplasmic 
and the transmembrane region has been shown to have effects on the cellular response to 
CEACAM1 binding. Generally, isoforms with a long cytoplamic tail have two immunoreceptor 
tyrosine-based inhibitory mofits (ITIMs) which are crucial for signal transduction. In addition, 
the cytoplasm of isoforms with long cytoplasmic tails contains amino acids like serine, 
threonine and tyrosine residues that can be phosphorylation targets for signal transduction. 
In contrast, the isoforms of CEACAM1 with a short cytoplasmic tail lack ITIM sequences but 
contain sequences that can bind to globulin actin, tropomyosin, and calmodulin (Edlund et 
al., 1996a; Schumann et al., 2001). Furthermore, the isoforms with short cytoplamic tail are 
phosphorylated at the serine and threonine sites. Both isoforms are co-expressed in most 
CEACAM1 expressing cells and the ratio between the two isoforms seems to influence the 
signal outcome (Turbide et al., 1997). In addition, the ratio is not static and can vary 
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according to the cell type, its growth phase and activation state (Singer et al., 2000; Greicius 
et al., 2003). 
  
 
 
 
 
 
 
 
 
    
 
 
 
Figure 3: Naturally occurring isoforms of human CEACAM1.  
The letters A and B next to the domains represent the two IgC-like domains. The number 
after CEACAM1 indicates the number of extracellular immunoglobulin-like domains, whereas 
the letter that follows this indicates the presence of either a long (L) or a short (S) 
cytoplasmic tail. In addition unique termini (C) or an Alu family represent a repeat sequence 
present within the open reading frame. Modified diagram from (Gray-Owen and Blumberg, 
2006). 
1.8 Expression of CEACAM1 
Human CEACAM1 shows a broad cellular expression pattern. The expression differs 
depending on activation states and growth phase of cells. It is expressed on most epithelial 
cells of esophagus, gallbladder, pancreas, renal proximal tubules, stomach, colon, liver, 
kidney cells in the proximal tubuli, urinary bladder, prostate, cervix, squamous, endometrium 
and sweat glands (Prall et al., 1996; Horst and Wagener, 2004; Obrink, 1997b). Furthermore, 
it was detected in the extralobular and terminal ducts and myoepithelial layer of the normal 
mature breast (Riethdorf et al., 1997). 
Furthermore, CEACAM1 is expressed on angiogenicly activated endothelial cells and is 
localized to the endothelial cells of new formed microvessels (Ergun et al., 2000b). 
Overexpression of CEACAM1 in vascular endothelial cells up-regulates potent-proangiogenic 
factors such as VEGF, Ang1 and Ang2 as well as lymphangiogenic factors such as VEGF-C 
and VEGFR-3 leading to reprogramming of vascular endothelial cells to a lymphatic 
phenotype (Kilic et al., 2005; Kilic et al., 2007). It is also expressed on various hematopoietic 
cell types such as granulocytes, B cells, T cells, natural killer (NK) cells and dendritic cells 
(Kammerer et al., 1998; Khan et al., 1993; Moller et al., 1996b; Singer et al., 2002; Watt et 
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al., 1991). CEACAM1 is rapidly upregulated on T cells by activation by cytokines such as 
interleukin-2 (IL-2), IL-7, IL-15 (Boulton and Gray-Owen, 2002; Kammerer et al., 1998). 
1.9 Physiological functions of CEACAM1 
1.9.1 Tumor suppressor 
A potential tumor suppressor role of CEACAM1 was first reported from studies with 
hepatoma cells (Hixson et al., 1985). Later, it has been shown that mRNA levels of 
CEACAM1 are down-regulated in some tumors such as colorectal and prostate carcinomas 
(Nollau et al., 1997; Lin and Pu, 1999). In addition, down regulation of CEACAM1 in prostate 
cancer has been shown to be associated with loss of cell polarity. Consequently, the 
proliferative activity of prostate cancer cells was increased four fold and expression of 
CEACAM1 was lost in transition to Gleason grade 4 (Busch et al., 2002). These results 
collectively led to hypothesis that CEACAM1 is a tumor-suppressor.  
A tumor suppressor is a protein that protects normal cells from becoming malignant. 
However, CEACAM1 did not fulfill this because, while down regulated in several tumor types 
it is also up-regulated in certain tumors. e.g. in gastric carcinomas, squamaous lung cell 
carcinomas (Ohwada et al., 1994) and in malignant melanomas (Thies et al., 2002). In 
addition it was reported that CEACAM1 does not cause but rather stabilizes and maintains 
contact inhibition (Singer et al., 2010).Therefore, detailed mechanisms of cell growth 
regulation mediated by CEACAM1 are still not understood. 
1.9.2 CEACAM1 in angiogenesis 
The first indication that CEACAM1 is involved in vessel development emerged from the 
findings that it is expressed on microvessels in the developing central nervous system of rat 
(Sawa et al., 1994). The first detailed analyses showing the expression of CEACAM1 in 
angiogenicly activated endothelial cells and newly formed small tumor vessels were 
published a decade ago (Ergun et al., 2000b). These authors could show that vascular 
endothelial growth factor (VEGF) increased CEACAM1 expression in the human primary 
endothelial cells (Ergun et al., 2000b). Analysis with cDNA arrays revealed that CEACAM1 is 
induced on microvessels of the left ventricle of chronically hypoxic rats as well as upon 
myocardial infarction of mice (Chen et al., 2005a). The vascular endothelial growth factor 
(VEGF) increased CEACAM1 expression in the endothelial cells (Ergun et al., 2000b). In 
addition, CEACAM1 expression was also increased in H9c2 cells (embryonic rat ventricle) 
after incubation with VEGF (Chen et al., 2005a). However, in CEACAM1-deficient mice a 
poor vascularization of implanted extracellular matrix gel that contain pro-angiogenic factors 
such as angiopoietin-1 and VEGF was observed (Horst et al., 2006). Therefore, CEACAM1 
appears to be involved in tumor angiogenesis, as it is expressed in endothelial cells of tumor-
associated small vessels but not in large and quiescent blood vessels (Kilic et al., 2005; 
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Muller et al., 2005; Oh et al., 2004b). Moreover, CEACAM1 overexpression in human primary 
endothelial cells resulted in up-regulation of pro-angiogenic factors and significantly better 
survival of these cells (Kilic et al., 2005). 
In addition, soluble CEACAM1 exhibit pro-angiogenic effect by stimulating proliferation, 
chemotaxis and capillary-like tube formation of human microvascular endothelial cells in 
vitro. Furthermore, it increased the vascularization of the chorioallantoric membrane of 
embryos in vivo (Ergun et al., 2000b) 
Therefore, molecular mechanisms behind CEACAM1´s angiogenic properties are currently 
unknown.  
1.9.3 Cellular adhesion molecule 
CEACAM1 can engage in homophilic (CEACAM1-CEACAM1) binding interactions. These 
homophilic bindings are regulated by trans-dimerization, the phosphorylation status of its 
cytoplasmic tail, its binding to calmodulin, and the activity of tissue transglutaminase (Obrink, 
1997a; Hunter et al., 1998). Examples of CEACAM1 function mediated by trans-homophilic 
adhesion include the establishment of tissue organization during embryonic development, 
neutrophils activation, inflammatory responses, regulation of T cells, and regulation of cell 
proliferation (Obrink, 1997b; Hammarstrom, 1999).  
At the epithelial–cell surface, CEACAM1 is found mostly as a cis-homodimer (Hunter et al., 
1996). This dimerization leads to different CEACAM1 signaling involving SRC-family kinase 
and SHP phosphatases (Obrink et al., 2002). The binding of calcium ions-calmodulin 
complex to the cytoplasmic region of CEACAM1 causes dissociation of cis-dimers in vitro 
(Hunter et al., 1996). It remains unknown whether the cis-dimers must dissociate before 
intercellular binding can ensue. However, recent studies have shown that trans-binding 
increases formation of cis-dimers ( Klaile et al., 2009a; Muller et al., 2009a). CEACAM1 
isoforms undergo dimerization, presumably allowing the formation of dimers (L:L, S:S; L:S). 
Therefore, equilibrium between monomeric and dimeric forms affects cellular responses.  
CEACAM1 anchored cell membranes also appeared as microclusters of closely packed 
proteins (Klaile et al., 2009a). Such clustering is expected, as predicted by (Grasberger et al., 
1986) who demonstrated the likelihood of cell surface proteins forming dimers and higher 
oligomers. 
It is well established that CEACAM1 mediates intercellular interaction via its N-terminal 
domain  (Watt et al., 2001; Markel et al., 2004a; Stern et al., 2005; Klaile et al., 2009a). In 
addition, it was shown that the trans-homophilic CEACAM1 binding induces cis-dimerization 
by an allosteric mechanism is transmitted via the N-terminal immunoglobulin-like domain 
(Muller et al., 2009a). Furthermore, trans-binding between the N-terminal domains changes 
CEACAM1 interactions with microcluster (Klaile et al., 2009a). However, it has been 
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suggested that the affinity of homophilc binding seems higher when multiple IgC2 domains 
are present (Stern et al., 2005).  
CEACAM1 is also involved in interactions with other proteins like E-selectin (Dransfield et al., 
1995), and pathogenic molecules (Virji, 2000; Gray-Owen et al., 1997; Hill et al., 2001). 
1.9.4 CEACAM1 as pathogen receptor 
The attachment of microorganisms to host surface structures is a key step for the bacterias 
to colonize the mucosal surfaces (Finlay and Falkow, 1997; Abraham et al., 1998).  
CEACAM-specific adhesins allows various bacterias to attach, invade and internalize into the 
host tissues. Adhesins are component of bacterias that facilitate adhesion to receptors on 
other cells. Pathogens such as Neisseria gonorrhoeae and Neisseria meningitides express 
opacity-associated (Opa) proteins that bind to CEACAM1 expressed on the membrane of 
epithelial cells (Virji et al., 1996; Virji et al., 2000; Gray-Owen et al., 1997; Boulton and Gray-
Owen, 2002; Wang et al., 1998). Studies have shown Opa proteins expressed by both 
Neisseria species which bind specifically to the N-terminal domain of the CEACAM1 (Gray-
Owen et al., 1997; Bos et al., 1999). Furthermore, detailed studies have shown that the β-
strand in the non-glycosylated GFC face of N-terminal region is usually the binding site 
(Cunningham et al., 1989; Nassif et al., 1999; Popp et al., 1999). The binding of these 
pathogens to the cells trigger an up regulation of CEACAM1 through inflammatory cytokines 
such as tumor necrosis factor (Muenzner et al., 2001). By this mechanism the pathogen is 
able to effectively colonize the host cell. 
Like gonococci the Hemophilis influenzae bind to CEACAM1 using adhesin P5 (Virji et al., 
2000) and the binding is through the N-terminal domain (Hill et al., 2001). However, other 
studies show that presence of A or B domains are required (Virji et al., 2000). 
Furthermore, UspA1 proteins has been identified as the Moraxella catarrhalis CEACAM1-
binding protein (Slevogt et al., 2007; Brooks et al., 2008). The binding also occurs through 
the N-terminal domain (Hill and Virji, 2003). 
The carbohydrates in CEACAM1 appears to be recognized by enterobacteria such as 
Escherichia coli and salmonella strains expressing Dr family of adhesins (Leusch et al., 
1991; Sauter et al., 1993). Furthermore, detailed studies have shown these interactions are 
via N-terminal domain (Korotkova et al., 2006). In addition, these pathogens might exploit the 
immunosuppressive capacity of CEACAM1.  
1.9.5 CEACAM1  as regulator of immune cell responses 
1.9.5.1 CEACAM1 role in T lymphocytes 
CEACAM1 is expressed on human T cells (Khan et al., 1993; Moller et al., 1996b). In 
addition, no other CEA family member except CEACAM1-4L and CEACAM3-3L has been 
characterized on T cells (Singer et al., 2002).  CEACAM1 is weakly expressed on the surface 
1 Introduction 
 25 
of resting T cells. However, it is significantly upregulated on T cells following activation by 
cytokines such as IL-2, IL-7, IL-15 (Boulton and Gray-Owen, 2002; Kammerer et al., 1998) or 
by stimulation through CD3/CD28 (Boulton and Gray-Owen, 2002; Moller et al., 1996b). The 
release of cytokines leads to priming of naive CD4+ T cells with a T helper 1 effector 
phenotype, favoring a tumor immune response (Kammerer et al., 2001; Singer et al., 2002). 
In  intestinal T cells activation through CEACAM1-L induces an increase of nuclear factor 
(NF)-kb and AP1 mediated transcription (Donda et al., 2000) and thus could facilitate 
crosstalk between epithelial cells and T lymphocytes in intestinal immune response. 
CEACAM1 can also act a co-inhibitor of T cells receptor (TCR) responses. This happens 
once CEACAM1 on the surface was bound by CEACAM1 specific antibodies (Kammerer et 
al., 1998; Morales et al., 1999), CEACAM1-specific Opa proteins of Neisseria gonorhoeae 
(Boulton and Gray-Owen, 2002) and when bound with soluble CEACAM1-Fc (Chen et al., 
2004). These ligands-CEACAM1 interactions have been shown to inhibit T cells cytokine 
production (IL-2), proliferation, and cytotoxic activity. Furthermore, CEACAM1 on T cells 
lacks the sialyl-Lewis moieties found on granulocytes (Lucka et al., 2005). 
1.9.5.2 CEACAM1 role in B lymphocytes 
CEACAM1 is constitutively expressed on human B cells (Khan et al., 1993; Singer et al., 
2002). The cytoplasmic domain of CEACAM1-L isoforms confers on FcуR11B the capacity to 
inhibit BCR-induced Ca2+ (Chen et al., 2001) mobilization a hall mark of co-inhibitory effect. 
This effect requires the tyrosine residues in the membrane-proximal and the ITIM of 
CEACAM1. This is mediated by SHP 1 and SHP 2 (Chen et al., 2004). 
In contrast to inhibitory effect, CEACAM1 is a prominent regulator of BCR-induced activation 
of B lymphocytes (Greicius et al., 2003). Antibodies against CEACAM1 in combination with 
cross-linking of the BCR stimulated cell proliferation, Ig secretion, and ß2 integrin-mediated 
homotypic adhesion, which are crucial processes in B cell function (Greicius et al., 2003). 
1.9.5.3 Neutrophilic granulocytes 
Neutrophils are the leukocyte type with the broadest CEACAM expression. They co-express 
CEACAM1, CEACAM3, CEACAM6, and CEACAM8. During neutrophilic development, 
CEACAM1 is expressed from the myelocyte stage and maintained through out mature 
neutrophils. It is significantly expressed on resting PMNs cells. Furthermore CEACAM1 
expression is rapidly upregulated upon stimulation with peptides such as formyl-methionyl-
leucyl-phenylalanine (fMLP), calcium ionophores and phorbol esters (Skubitz et al., 1992; 
Kuroki et al., 1992; Stocks and Kerr, 1993).  
Ligation of CEACAM1 with monoclonal antibody addressing N-domain stimulates β2-integrin-
dependent neutral aggregation (Kuijpers et al., 1993) and adherence of neutrophils to 
HUVECs (human umbilical vein endothelial cells) (Kuijpers et al., 1992). Furthermore, 
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synthetic peptides containing sequences of the N-terminal domain of CEACAM1 can initiate 
signal transduction in neutrophils and are involved in interaction of CEACAM1 with other 
ligands (Skubitz et al., 2001; Skubitz and Skubitz, 2010). 
1.9.6 Role of CEACAM1 in insulin regulation  
The binding of insulin to insulin-receptor (IR) activates tyrosine kinase to cause its 
phosphorylation and that of other endogenous substrates including CEACAM1. CEACAM1 
was originally identified as a substrate of insulin receptor tyrosine kinase in rat (Rees-Jones 
and Taylor, 1985). In addition, the binding causes CEACAM1 to be recruited into the IR-
insulin complex (Choice et al., 1998; Najjar et al., 1998). This process leads to 
phosphorylation of CEACAM1 at Tyr-488 which requires an intact ser-503 residue in the 
cytoplasmic tail (Najjar, 2002a). Furthermore, this CEACAM1 phosphorylation promotes 
endocytosis of the IR-insulin complex leading to insulin degradation in lysosomes (Najjar, 
2002a). It has been shown that N-terminal domain is crucial for enhancing insulin 
endocytosis (Soni et al., 1999). 
  
2 Materials and Methods 
 27 
2. Materials and Methods 
2.1 Materials 
2.1.1 Chemical and consumables 
 
Chemicals Supplier 
 
Acrylamide Serva (Heidelberg) 
Agarose PeqLab (Erlangen) 
Ampicillin Sigma (Taufkirchen) 
APS  Merck (Darmstadt) 
Bovine Trypsin Sigma-Aldrich (Steinheim) 
Coomassie Brillant Blue G-250 BioRad (München) 
DMEM Gibco BRL (Karlsruhe) 
DMSO Merck (Darmstadt) 
DTT BioRad (München) 
EDTA Serva (Heidelberg) 
FCS Gibco BRL (Karlsruhe) 
Hydrogen peroxide Sigma (Taufkirchen) 
Glycerol AppliChem (Darmstadt) 
Glycin Roth (Karlsruhe) 
Iodacetamide Sigma (Taufkirchen) 
LE Agarose Biozym scientific (Oldendorf) 
L-Glutamine Gibco BRL (Karlsruhe) 
Milk powder- Non fat AppliChem (Darmstadt) 
Nonidet (NP-40) Calbiochem (Darmstadt) 
Nitrocellulose-Membrane Millipore (Germany) 
Oligonucleotides (Primers) MWG Biotech (Ebersberg) 
Page Ruler Prestained Protein Ladder Fermentas (USA) 
PBS Gibco BRL (Karlsruhe) 
TEMED Sigma (Taufkirchen) 
Tricine AppliChem (Darmstadt) 
Tris AppliChem (Darmstadt) 
Triton X-100 Sigma (Taufkirchen) 
Trypsin/EDTA (1x) Gibco BRL (Karlsruhe) 
Urea Sigma (Taufkirchen) 
Cell culture flasks, plates, and tubes Falcon (Heidelberg) 
Table 2: Chemicals used and their supplier 
2.1.2 Kits 
 
Product 
 
Supplier 
 
 
BCA Protein Assay Kit Pierce (USA) 
Micro BCA Protein Kit Pierce (USA) 
RNeasy Mini Kit Qiagen (Germany) 
QuantiTech Reverse Transcrition Kit Qiagen (Germany) 
Centricon Columns Sartorius Stedim Biotech (Germany) 
2 Materials and Methods 
 28 
ReadyPrep Sequential Extraction Kit BioRad (Germany) 
IPG Strips (11.17 cm) pH 3-10 BioRad (Germany) 
Criterion Precast Gel BioRad (Germany) 
DAKO QIFIKIT DAKO (Netherlands) 
TMB Liquid Substrate System SIGMA (USA) 
PNGase F Kit NEW ENGLAND BioLabs (USA) 
Ficall-paque Plus GE Healthcare (United Kingdom) 
Fluitest UST Kit Biocon Diagnotics (Germany) 
Proteoprep Blue Albumin & IgG Depletion Kit SIGMA (USA) 
PIERCE Direct IP Kit Pierce (USA) 
Table 3: Kits used and the suppliers name 
 
2.1.3 Stock solutions and buffers 
Tricine SDS polyacrylamide gels 
Tricine gel buffer pH 8.45 
SDS 0.3% (w/v)                          1.5g 
Tri-HCl (3 M)                              181.71 g 
Adjust to 500 ml with deionized H2O 
 
1x Cathode buffer pH 8.3  
Tricine (0.1 M)                               17.92 g 
SDS 0.1% (w/v)                             1 g  
Tris-HCL (0.1 M)                            12.1 g 
Adjust to 1000 ml with deionized H2O 
 
1x Anode buffer pH 8.9 
Tris-HCl (0.2 M)                              24.23 g 
Adjust to 1000 ml with deionized H2O 
 
SDS polyacrylamide gels 
Separating gel buffer pH 8.8 
SDS 0.4% (w/v)                                 0.8 g 
Tris-HCL (1.5 M)                               36.3 g 
Adjust to 200 ml with deionized H2O 
 
Stacking gel buffer pH 6.8 
SDS 0.4% (w/v)                                0.4 g  
Tris-HCL (0.5 M)                               6.0 g 
Adjust to 100 ml with deionized H2O 
 
 
 
 
 
10x SDS running buffer pH 8.8 
Glycin (2 M)                                       144 g 
SDS 1% (w/v)                                    10 g 
Tris-HCL (250 mM)                            30 g 
Adjust to 1000 ml with deionized H2O 
 
1x blotting buffer pH 8.4 
Glycin (133 mM)                               40 g 
Tris (12 mM)                                       6 g 
Adjust to 4 liters with deionized H2O 
 
 
1X TBS Wash buffer pH 7.6 
Tris-HCL (20mM)                           2.42 g 
NaCl (137mM)                                8.01 g 
Adjust to 1000 ml with deionized H2O 
 
Western blot detection solution A 
Courmaric acid (6.8 mM)                0.112 g  
Adjust to 100 ml with DMSO (H2O free) 
 
Blot detection solution B pH 8.5 
Luminol (1.25 mM)                            0.22 g 
Tris-HCL (0.1M)                               12.1 g 
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Adjust to 1000 ml with deionized H2O 
 
 
Blot detection solution C 
H2O2 3% (v/v)                                   10 µl 
H2O                                                   90 µl 
 
Preparation of Western blot detection 
solution 
Solution A                                         15 µl 
Solution B                                         1 ml 
Solution C                                         3 µl 
 
5x SDS sample buffer pH 6.8 for 10 ml 
Tris-HCL (500 mM)                         0.61 g 
Glycerol 75% (v/v)           7.5 ml 
SDS 15% (w/v)            1.5 g 
Bromophenole blue 0.125 % (w/v) 12.5 mg 
Adjust to 10 ml with distilled H2O 
75 mM β-mercaptoethanol (fresh) 
 
Coomassie staining solution 
Acetic Acid                                 10% (v/v) 
Ethanol                                       50% (v/v) 
Coomassie Brillant Blue G-250 0.5% (w/v) 
 
Commassie destaining solution 
Acetic Acid                                  5% (v/v) 
Ethanol                                        10% (v/v) 
 
Silver staining solution 
Fixation solution 
Ethanol 50% (v/v)                          500 ml  
Acetic acid 12% (v/v)                     120 ml 
From 35% Formalin                        500 µl 
Adjust to 1000 ml with deionized H2O 
Wash solution 
Ethanol 20% (v/v)                        200 ml    
Adjust to 1000 ml with deionized H2O 
 
Sensitizing solution 
Sodium Triosulfate 0.02% (w/v) 200 mg  
Adjust to 1000 ml with deionized H2O 
 
Staining solution (freshly prepared) 
Deionized H2O                              75 ml     
From AgNO3 10% (v/v)                  8 ml 
From 35% Formalin                      76.4 µl 
Adjust to 100 ml with deionized H2O 
 
Developing solution 
Na2CO3 6% (w/v)                           60 g      
Na2S2O3 0.004% (w/v)                   4mg   
From 35% Formalin                       500 µl 
Adjust to 1000 ml with deionized H2O 
 
Terminating solution 
Acetic acid 12% (v/v)                     120 ml 
Adjust to 1000 ml with deionized H2O 
 
Nitro blue staining 
Reduced Glutathione buffer pH 9.6 
Reduced glutathione                         8 mM 
Tris-HCL                                           0.1 M 
 
Nitroblue tetrazolium buffer pH 9.6 
NBT                                                 1 mM    
Tris                                                   0.1 M 
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RIPA Lysis buffer  
Phosphate buffer 0.01M pH 7.2
KH 2PO4         0.41 g 
  250 ml  
Na2 HPO4         1.25 g 
Phosphate buffer (Solution)
From 10% SDS 0.1% (v/v)       2.5 ml 
       200 ml 
Triton X-100 1% (v/v)        2.5 ml 
Sodium Deoxycholate 1% (w/v)  2.5 g 
Sodium Flouride 50 mM      0.52 g 
NaCl 150 mM                   2.19 g 
EDTA  2 mM                              0.15 g  
Adjust the volume using phosphate buffer 
Adjust the 7.2 pH with 1N NaOH 
Protease inhibitor cocktail (fresh) 
 
2D-PAGE Rehydration Buffers 
Urea          5 M 
2D-PAGE Equilibration Buffer I 
SDS          20% (w/v) 
Tris-HCl (pH 8.8)                  1.5 M 
Glycerol                   50% (w/v) 
DTT (fresh)                  0.5% (w/v) 
 
Urea        5 M 
2D-PAGE Equilibration Buffer II 
SDS        20% (w/v) 
Tris-HCl (pH 8.8)                1.5 M 
Glycerol       50% (w/v) 
Iodacetamide (fresh)                 2.5% (w/v)  
 
 
 
 
Reagent 2 (ReadyPrep Sequential 
Extraction Kit) 
 
Urea        8 M 
CHAPS       4% (w/v) 
SB 3-10       2% (w/v) 
Tris        40 mM 
Biolyte3-10                  0.2% (v/v) 
TBP (fresh)                  2 mM 
75 mM β-mercaptoethanol (fresh) 
Bromphenolblue                  trace 
 
Reagent 3 (ReadyPrep Sequential 
Extraction Kit) 
 
Urea        5 M 
Thiourea       2 M 
CHAPS       2% (w/v) 
SB 3-10       2% (w/v) 
Tris        40 mM 
Biolyte 3-10                  2% (v/v) 
TBP (fresh)                  2 mM 
DTT (fresh)                  0.5% (w/v) 
Bromphenolblue                  trace 
 
50x TAE Buffer pH 7.5 
Tris-Base        2 M  
Glacial acetic acid       5.7% (v/v) 
EDTA                                          50 mM 
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2.1.4 Equipment and appliance 
 
 
Instruments 
 
Supplier 
Autoclave Thermo Scientific (USA) 
Centrifuge 5415D Epperdorf (Humburg) 
Centrifuge Sorvall Rc5c Plus Thermo scientific (USA) 
Cold Centrifuge Micro 200R Hettich Zentrifugen (Tuttlingen) 
Cold Centrifuge ROTINA 38R Hettich Zentrifugen (Tuttlingen) 
ELISA Reader TECAN (USA) 
FACS Calibur Beck Dickinson (USA) 
Gel electrophorsis Apparatus BioRad (USA) 
Gel Ducumentation system LAS-300RG Fiji-Film (Düsseldorf) 
Thermo Block Grant (USA) 
Magnetic mixers Heidolph (Kelheim) 
Voltex IKA (Staufen) 
Water Bath  WTW (Weiheim) 
Cells incubator Heraeous Instruments (Hanau) 
Light Microscope ZEISS (Jena) 
PCR iCycler  BioRad (USA) 
Vacuum hood NuAire (USA) 
pH Meter  WTW (Weilheim) 
Rotator SB2 Stuart Stuart 
Balances Gunten (Bot-Kirchhellen) 
Gel Imager uv- Systeme Intras (Göttigen) 
Shakers IKA (Staufen) 
Table 4: All equipments used  
2.1.5 Antibodies 
 
Antibody 
 
Source Supplier 
Anti-hCEACAM1 (Clone B3) Mouse 
CEACAM1 
Kindly provided by Dr. Bernhard B. Singer 
(Institute of Anatomy, University Hospital 
Essen) 
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Anti-hCEACAM1 (Clone C5-1X) Mouse 
CEACAM1 
 
Kindly provided by Dr. Bernhard B. Singer 
(Institute of Anatomy, University Hospital 
Essen) 
Anti-hCEACAM1 (Clone 18/20) Mouse 
CEACAM1 
CEACAM3 
CEACAM5 
Kindly provided by Dr. Bernhard B. Singer 
(Institute of Anatomy, University Hospital 
Essen) 
Anti-hCEACAM1 (Clone 4/3/17) Mouse 
CEACAM1 
CEACAM5 
Kindly provided by Dr. Bernhard B. Singer 
(Institute of Anatomy, University Hospital 
Essen) 
Anti-hCEACAM1 (Clone 
4D1/C2) 
Mouse 
CEACAM1 
Kindly provided by Professor Dr. Wagener. 
(Institute of Urology, University Hospital 
Hamburg-Eppendorf) 
Anti-hCEACAM1 (Cat No. 
AF2244) 
Mouse 
CEACAM1 
R&D Systems 
Anti-hCEACAM1 (Clone 283340) Mouse 
CEACAM1 
R&D Systems 
Polyclonal Anti-Human 
Carcinoembryonic Antigen 
Rabbit  
All 
CEACAM´s 
DAKO (Netherlands) 
Anti-hCEACAM1 (Clone 8G5) Mouse 
CEACAM1 
Genovac Freiburg 
Table 5: primary antibodies  
 
Antibody Source Working Dilution Supplier 
Anti-Mouse IgG F(ab´)2 Fragement HRP  
 
Mouse 1:5000 Jackson 
ImmunoResearch 
Anti-Mouse IgG (H+L) HRP Mouse 1:5000 Jackson 
ImmunoResearch 
Anti-Human CD25 FITC Mouse 1:40 ImmunoTools 
Anti-Human CD69 Dy647 Mouse 1:40 ImmunoTools 
Anti-CD3 PE Mouse 1:40 EXBIO Praha 
Anti-Mouse IgG F(ab´)2 Fragement  
FITC 
Mouse 1:40 Jackson 
ImmunoResearch 
 
Table 6: secondary HRP antibodies 
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2.1.6 Cell lines and medium for cultivation 
 
 
Cell line 
 
Characteristics 
 
Source 
A549 Lung carcinoma epithelium 
cells 
PromoChem (Wesel, Germany) 
HT29 
 
Human colon adenocarcinoma  DSMZ (Braunschaweig, 
Germany) 
 
T102/3 Human colon adenocarcinoma  Kindly provided by PD Dr. 
Robert Kammerer (Institute of 
Immunology, Fridrich Loeffler 
Institute Tuebigen) 
AS-M.5 Cutaneous angiosarcoma 
derived LEC 
Kindly provided by Vera 
Krump-Konvalinkava (Institute 
of Pathology, Johannes 
Gutenberg Univeris Mainz) 
HeLa-CEACAM1 Human cervix carcinoma 
transfected with CEACAM1 
Kindly provided by Dr. 
Bernhard B. Singer (Institute of 
Anatomy, University Hospital 
Essen) 
Table 7: Cell lines used in the study 
The Dulbecco´s modified Eagle’s medium (Gibco) was supplemented with 10% (v/v) heat-
inactivated FCS (PAA), 2 mM L-glutamine (Gibco), 100 Lµ/ml penicillin (Gibco),100 µg/ml 
streptomycin (Gibco) and pre-warmed to 37oC prior to use. Fetal bovine serum was heat 
inactivated at 65°C for 30 minutes before use. The cells were grown in 5% CO2 humidified 
atmosphere at 37o C. 
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2.2 Methods 
2.2.1 Protein analysis 
2.2.1.1 Extraction of protein 
Adherent cells were removed from the flask by 0.05% trypsin-EDTA transferred into 3 ml 
10% FCS medium. Both adherent and suspension cells were centrifuged for 3 minutes at 
250 x g, and then washed with cold PBS. The cell pellets were resuspended in RIPA-lysis 
buffer which contains protease inhibitor (1:100), vortexed and incubated on ice for 10 
minutes. The samples were sonicated (Bundelin sonopuls, Germany) at 5 x 10% cycles for 5 
seconds pulses. Then, the samples were centrifuged for 10 minutes at 18620 x g at 4°C. The 
supernatant were collected and kept at -20°C until further analysis. The protein concentration 
was determined using one of the following methods, BCA Protein Assay, Bradford Assay or 
Fluitest USP kit. 
2.2.1.2 BCA protein assay- Pierce 
Protein concentration was measured utilizing the bicinchoninic acid (BCA) method. The 
standard curve was determined according to manufacture’s instructions. The BSA (Bovine 
Serum Albumin) was diluted in 0.9% NaCl or 50 mM Tris buffer. The standards and 
appropriate diluted samples (1:5) were measured in duplicates. The working reagent (WR) 
was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA Reagent B (50:1, 
Reagent A: B) while it’s total volume was calculated using the formulae below. 
 
(# Standards + # unknowns) X (# replicates) X (volume of WR per sample = total volume WR 
required. 
1 ml of working reagent was added to cuvettes, and was incubated at 37°C for 30 minutes, 
then allowed cooled at room temperature before the absorbance measurements at 562 nm. 
Sample protein concentrations were estimated applying the BSA standard curve. 
2.2.1.3 Micro BCA protein assay- Pierce 
The Kit was utilized to determine low concentrated protein samples 0.5 µg/ml - 20 µg/ml. The 
kit uses concentrated reagents and its performance needs an incubation time of 1 hour at 
60oC. The working reagent was prepared by mixing 25 parts of MicroBCA Reagent MA, 24 
parts Reagent MB with 1 part Reagent MC. The protein concentrations were determined 
using bicinchoninic acid (BCA) according to the manufacturer’s manual. Sample protein 
concentrations were estimated applying BSA standard curve. 
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2.2.1.4 Bradford assay-BioRad 
Bradford´s method was performed as described by (Bradford, 1976). BioRad Protein assay 
kit was used and bovine IgG (gamma globulin) was used as the standard, dilute in PBS from 
0.2 mg/ml to 1.5 mg/ml. The samples were diluted in PBS (1:10) and 10 µl was applied the 
protein concentration determination. The working reagent was prepared by mixing 1 part of 
reagent and 4 parts of H2O. From the working reagent 500 µl was used. The absorbance 
was measured at 595 nm and protein concentration determined applying the IgG standard 
curve. 
2.2.1.5 Fluitest USP kit 
Fluitest test USP kit from Biocon Diagnostics, Germany was used for the protein 
determination. In this method pyrogallol-red-molybdate complexes are bound to proteins. 
The binding causes a shift of absorbance peak. The increase of absorbance is directly 
proportional to the protein concentration. The standard curve was prepared by adding 10 µl 
of reagent 4 into two wells in an ELISA plate. Then 10 µl of protein samples were transferred 
into two different well, subsequently 240 µl of reagent 1 was to all wells. For the blank 250 µl 
of reagent 1 was transferred into different wells. The plate was then incubated at room 
temperature for 10-30 minutes before the absorbance of the samples were measured in an 
ELISA reader at 620 nm. The assay was performed in triplicates. 
2.2.1.6 Tricine polyacrylamide gel electrophoresis 
Tricine-SDS-PAGE developed by (Schagger and von, 1987). In this technique tricine 
replaces glycine in the running buffer resulting in more efficient stacking and disstacking of 
low molecular weight proteins (5-20 kDa) and high resolution of smaller proteins. Tricine ions 
migrate ahead of proteins thus improving the separation of small size proteins at lower 
acrylamide concentrations than in the SDS-PAGE systems. Proteins above 30 kDa are 
disstacked within the stacking gel thus helping in smooth migration of these proteins in to the 
separation gel. Tricine does not interfere with the amino acid sequencing. In addition, to good 
transfer efficiency, the tricine system has a lower pH which minimizes unwanted protein 
modification. Tricine polyacrylamide gels were prepared using the following protocol. 
 
             Separation gel 
Solutions 9% 11% 
30% Arcylamide/Bisaryclamide 2.25 ml 2.75 ml 
Tricine gel buffer 2.5 ml 2.5 ml 
H2O 2 ml 1.5 ml 
Glycerine 1 g 1 g 
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APS 10% (w/v) 37.5 µl 37.5 µl 
TEMED 3.75 µl 3.75 µl 
Table 8: Reagents and buffer for preparing tricine separation gel 
 
                     Stacking gel 
Solutions 4% 
30% Arcylamide/Bisaryclamide 0.83 ml 
Tricine gel buffer 1.55 ml 
H2O 3.8 ml 
APS 10% (w/v) 50 µl 
TEMED 5 µl 
Table 9: Reagents and buffer for preparing tricine stacking gel. 
 
In most cases 9% and 11% of Tricine gels were used in combination with 4% of stacking gel 
buffer to allow optimum separation. High percentage gels were used because they separate 
large molecular weight proteins better than low molecular weight proteins. The cassettes 
were filled up to approximately 5 cm with the separating gel mixture, then immediately the 
stacking gel was poured on to the top. A 10 or 15 comb was inserted to create the pockets 
for sample loading. The gel was allowed to polymerize for 30 minutes, at room temperature. 
After polymerization, the comb was carefully removed. The cassettes containing the gels 
were vertically inserted into the electrophoresis chamber and filled with tricine running 
buffers. For tricine gel electrophoresis two different running buffers were used. The middle 
chamber between the gels was filled with cathode buffer while the outer chamber with anode 
buffer. The samples were mixed well with equal volume of 5X laemli sample buffer to give a 
final concentration of 2.5X with subsequent reduction by addition of 75 mM of Beta-
merptoethanol. Then the samples were boiled at 95o C for 10 minutes. Prestained protein 
marker from Fermentas was used to estimate molecular size of separated proteins. Then the 
prepared samples were loaded using Hamilton syringe. The gels were run first at 45°C to pull 
down the samples to the separation gel slowly and then increased to 120 volts. The gel was 
then removed from the cassette and proteins transferred on a nitrocellulose membrane. 
2.2.1.7 SDS–Polyacrylamide gel electrophoresis 
Protein samples were separated in a denaturing sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) system (Laemmli, 1970). Most case 10% gels were used. To 
prepare the samples for SDS-PAGE separation, first the samples were reduced by addition 
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of laemmli sample buffer in 1:1 v/v (from 5X stock) and subsequent reduction by addition of 
75 mM β-mercaptoethanol. Then the samples were heated for 10 minutes at 95oC. 
SDS-PAGE cassettes from Bio-Rad were used for gel preparation and the gels were 
prepared as follows. 
                  Separation gel  
Solutions 10% 
30% Acrylamide/ Bis-Arcylamide 3 ml 
Separation Buffer 2,25 ml 
H20 3.75 ml 
APS 10% (w/v) 45 µl 
TEMED 4.5 µl 
Table 10: Reagents and buffer for preparing SDS-PAGE separation gel. 
 
                      Stacking gel 
Solutions 4% 
30% Acrylamide/ Bis-Arcylamide 0.4 ml 
Separation Buffer 0,75 ml 
H20 1,85 ml 
APS 10% (w/v) 12 µl 
TEMED 3 µl 
Table 11: Reagents and buffer for preparing SDS-PAGE stacking gel. 
 
The cassettes were filled up to approximately 5 cm with the separating gel mixture and a thin 
layer of water was added to flatten the top of the separation gel also to prevent its 
evaporation. Then it was allowed to polymerize for 30 minutes at room temperature. After 
polymerization water is poured off and immediately the stacking gel mixture added on top. 
The sample preparation and the loading were done in the same ways as in tricine gel 
electrophoresis. SDS running buffer was used. After the separation was completed the 
proteins were transferred in to the nitrocellulose paper. 
2.2.1.8 Western blotting 
After efficient separation of proteins inside Tricine-SDS-PAGE or SDS-PAGE, proteins were 
transferred into nitrocellulose membrane (Millipore) using wet transfer inside electric field 
(Western blotting). For blotting nitrocellulose membranes were cut in size as 7x9 cm. The 
nitrocellulose membrane, sponges and Whatman filter papers were first soaked in blotting 
buffer shortly before placing. The Western blot chamber was arranged as follows. To 
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assemble transfer set the thick sponge was placed on the anode side of the transfer unit 
followed by three Whatman filter papers, then nitrocellulose membrane. And the gel was 
placed on it, covered with two Whatman papers and a thin sponge on the cathode side. Air 
bubbles were removed from the whole transfer set by rolling a glass over it from left to right. 
For transferring of proteins from gel to nitrocellulose membrane, equipments as Mini Trans-
Blot-System obtained from BioRad were used according to the manufacturer’s 
recommendations. The cassettes were placed in the chamber and a cold pack was put 
beside and filled with pre-chilled 1x blotting buffer. Electrophoretically transfer was performed 
1 hour using 100 voltages. Quality of the gel was confirmed by staining the membrane with 
ponceau red dye solution. The blot was incubated for 1-2 hours at room temperature or at 
4oC overnight in 3% non-fat dry milk dissolved in TBS buffer to block the remaining surface of 
the membrane to prevent nonspecific binding of the detection antibodies during subsequent 
steps. Then, the memrane was incubated with primary antibody (8 µg/ml) 3% milk/TBS 
solution at 4°C over night or 2-4 hours at room temperature. After incubation, the membrane 
was washed three times in TBS buffer with five minute interval to remove unbound 
antibodies. Then, secondary horseradish peroxidase (HRP) conjugated antibody solution 
(1:5000) was added for 1-2 hours at room temperature diluted in 1.5% non-fat dry milk power 
in TBS buffer. After three washing steps, the membrane was developed by chemiluminence 
and visualized by LAS 3000 Imager (Fiji- film). All incubations were performed on a shaker. 
2.2.1.9 Immunoprecipitation 
The cellular extracts, cell culture supernatants, feces and urine probes were incubated for 1 
hour at 4°C with 40 µl of protein G sepharose 4 Fast Flow beads (GE Healthcare) for 
preclearance. Then, the samples were centrifuged for 1 minute at 800 x g and the 
supernatant transferred into new tubes. After centrifugation, 2-10 µg of monoclonal 
antibodies against CEACAM1 or polyclonal rabbit anti-Human carcinoembryonic antigen 
(DAKO) was added and incubated for 2 hours at 4°C under permanent rotation. Then, 60 µl 
of protein G sepharose beads were added to the samples and further incubated at 4°C 
overnight under permanent rotation. The antigen-antibody-protein G beads complexes were 
pelleted by centrifugation at 400 x g for 1 minute, washed three times with 1x PBS. Then, 
added in 60 µl of 2.5x Laemli sample buffer containing 75 mM β-mercaptoethanol, and boiled 
at 980C for 10 minutes. Subsequently the samples were centrifugated at 2300 x g for 5 
minutes and the supernatant transferred into fresh tube. Fractions of the probes were loaded 
on an 11% tricine gel electrophoresis followed by transfer onto nitrocellulose membrane. 
2.2.1.10 PIERCE direct immunoprecipitation Kit. 
The immunoprecipitation was performed using the PIERCE DIRECT IP KIT (Thermo 
scientific). The beads were first coupled with 10 µg of mouse monoclonal anti-CEACAM1 
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antibody according to manufacture instructions. The coupling elution supernatants were kept 
for controling of coupling efficiency by Western blot and ELISA. After, coupling A549 cells 
were lysed using the lysis buffer provided in the Kit. The protein concentration in the lysate 
was determined using Fluitest USP Kit. 585 µg of cell lysates was transferred into two tubes 
one contained the anti-CEACAM1 coupled beads while the other Pierce control agarose 
resins. The samples were incubated overnight at 4oC under permanent rotator. Next the 
antigen-antibody-beads complexes were pelleted by centrifugation at 400 x g for 1 minute, 
washed three times with PBS. The proteins were eluted using elution buffer provided in the 
kit and immunoprecipitation flow through were kept for controlling of the efficiency of 
immunoprecipitation by Western blotting. Then the proteins were separated via 9% tricine 
gels, blotted and subsequently detected for CEACAM1. 
2.2.1.11 Protein deglycosylation 
Deglycosylation was performed using PN Gase F and additional reagents as provided by the 
supplier (New England Biolabs). The use of enzyme PNGase F is the most effective method 
of removing virtually all N-linked oligosaccharides from glycoproteins. The enzyme cleaves 
between the innermost GlcNaC and asparagine residues of high mannose, hybrid and 
complex oligosaccharides from N-linked glycoproteins (Maley et al., 1989).  
                
 
 
Figure 4: Chemical reaction illustrating the cleaving site of PNGase enzyme on the 
oligosaccharides. 
PNGase F hydrolyzes nearly all types on N-glycan chains from glycopeptides/proteins. 
[X=sugar(S)]. Obtained from New England Biolabs. 
 
First immunoprecipitation was performed to precipitate CEACAM1 from various cells (A549, 
T102/3, HT29 and AS-M.5) and from 40-50 ml of urine as described above. The antigen-
antibody-beads complexes were suspended in 55 µl of denaturing buffer which contained 
450 µl deionized H2O, 60 mM DTT, 50 µl 10x glycoprotein denaturing buffer supplied by 
manufacturer and subsequently boiled at 98oC for 10 minutes. Then, the beads were 
centrifuged at 2300 x g for 5 minutes. The supernatant containing eluted proteins was 
carefully transferred into new tube. Samples were divided into two fractions for non-
deglycosylated and deglycosylated probes. To prepare the total final volume of 30 µl probes 
the following master mix was prepared as shown below (Table 12).  
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       Components          Non-deglycosylated           deglycosylated 
 
            Protein probes                                  22 µl                                22 µl 
           10x G7 reaction buffer                      3 µl                              3 µl  
 10% NP 40                                        3 µl                               3 µl  
 H2O                                                    2 µl                                    -   
 PNGase                                              -                                       2 µl 
    
 Total volume (per probe)              30 µl                                  30 µl 
Table 12: compostion of deglycosylation reaction 
The samples mixed by vortexing and centrifuged briefly. For the digestion the samples were 
placed for 1 hour at 37oC. Reaction was stopped by addition of 5x SDS buffer and boiling at 
98oC for 10 minutes. Then, the samples were subjected to Western blotting as above 
described.  
2.2.1.12 Coomassie staining 
Coomassie Blue is a disulfonated triphenylmethane textile dye which was introduced for 
protein detection (Fazekas de St et al., 1963). The dye can be found in two modifications of 
Coommassie G-250 (greenish tint, dimethylated form) or R-250 (reddish tint). In acidic 
solution the dye sticks to the amino groups of the proteins by electrostatic and hydrophobic 
interactions. The technique has a detection limit of 50-100 ng. The staining may be done in 
presence of alcohol (methanol, ethanol or isopropanol up to 45%) and acid (acetic acid, 
trichloroacetic acid). The distaining of the gel is performed with similar solution but which do 
not have the dye (Chrambach et al., 1967; Weber and Osborn, 1969). In this technique the 
proteins have a higher affinity to the dye than the gel matrix, therefore distaining can be 
carried out until the background is low and the protein bands are clearly visible.  
The gels with separated proteins were placed into coomassie staining solution containing 
coomassie blue G-250 (sigma) for 2 hours at room temperature or overnight at 4oC. Then the 
gels were incubated gels in destaining solution for 2-4 hours at room temperature or until 
protein bands were clearly visible. 
2.2.1.13 Silver staining 
After the gel electrophoresis the tricine or SDS-PAGE gels were further stained with silver 
staining technique which has higher sensitivity than Coomassie staining. The technique 
provides a very sensitive tool for protein visualization with a detection level down to the 0.3-
10 ng level (Switzer, III et al., 1979). The mechanism underlying silver staining of protein or 
peptides in gels are well understood. Protein detection depends on the binding of silver ions 
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to the amino acid side chains mainly the sulfhydril and carboxyl groups of proteins (Switzer, 
III et al., 1979; Merril et al., 1981a) then followed by reduction to free metallic silver 
(Rabilloud, 1990). The protein bands are visualized as spots where the reduction occurs and 
this is based on the difference in oxidation-reduction reaction between the gel’s area 
occupied by proteins and the unoccupied regions.  
The gel was placed into a tray containing appropriate volume of fixation buffer for 2 hours at 
room temperature or at 4oc overnight to restrict protein movement from the gel matrix and to 
remove interfering compounds present in the gel. Fixation buffer contains formaldehyde thus, 
introducing the chemical modification into proteins by causing the cross-linking of two lysine 
residues within protein chains. Fixation buffer was discarded to a chemical compatible 
container with a sealed lid and labeled clearly because it can cause severe health problems 
if swallowed, inhaled or absorbed through the skin. The gel was washed in 20% ethanol for 
20 minutes at room temperature. The wash step was repeated three times. 
Alternatively, coomassie stained gels were silver stained to visualize bands which could not 
be detected. Here no additional fixation step was needed. After washing, enough volume of 
sensitizing solution was added and incubated for 2 minutes by gentle shaking at room 
temperature; this further increased the sensitivity and the contrast of the staining. Then, the 
gel was washed twice one minute each in deionized water. Then pre-cooled silver staining 
solution was added to the gel, incubated for 20 minutes at room temperature to allow the 
silver ions to bind to proteins. The staining solution was not poured directly on the gels at it 
may result in unequal background, in this it was added to the corner of the tray. After staining 
was completed, the staining solution was discarded and the gel rinsed twice with a large 
volume of deionized water for 20-60 seconds to remove the excess of unbound silver ions. 
Washing the gel for more than 1 minute was avoided because it would remove the silver ions 
from the gels resulting in decreased sensitivity. 
The gel was rinsed shortly with developing solution and immediately a fresh portion of 
developing solution was added, incubated for 2-5 minutes. As soon as the desired intensity 
of the bands was reached the reaction was stopped by adding of stopping solution. The gel 
was documented in Fiji gel documentation system. 
2.2.1.14 NitroBlue staining 
The technique allows the negative staining of proteins (Taketa et al., 1986). The gel matrix is 
stained blue by photoreduction of Nitro Blue Tetrazolim (NBT) into formazan while the protein 
bands remain unstained. The method is much more sensitive that Coommassie with a 
detection limit of 10-100ng. 
Immediately after gel electrophoresis, the gel was rinsed in deionized water, and then placed 
in a Tris buffer containing reduced glutathione-GSH (Sigma).Then the gel was incubated for 
15 minutes at room temperature. After incubation the gel was rinsed with deionized water 
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before staining in Tris containing nitroblue tetrazolium. The entire gel was stained dark blue 
after incubation of 2 minutes at room temperature, except for unstained protein bands. The 
staining was halted by rinsing the gel in deionized water. 
2.2.1.15 Two dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
Two-dimensional electrophoresis (2D-electrophoresis) was first introduced by (O'Farrell, 
1975) and (Klose, 1975). The technique separates protein mixtures in the first dimension 
according to their isoelectric point (pI) and in the second dimension by their molecular weight 
(MW) as shown in the figure below.  
 
 
Figure 5: Cartoon of 2D-SDS-PAGE.  
Proteins are separated in two dimensions horizontally by iso-electric point (pI) and vertically 
by molecular weight (MW) and each spot corresponds to a single protein. 
2.2.1.16 Urine collection  
Urine samples were collected from healthy male and female individuals. The first morning 
urine specimens were collected, a portion analyzed as fresh while the rest stored at -20°C 
(for a longer time than 2 months at -80°C) until use. Sodium azide (NaN3) was added to 
inhibit bacterial growth. Before any analysis was performed the samples were centrifuged at 
2300 x g for 10 minutes to remove cell debris. 
2.2.1.17 Preparation of urine samples for 2-DE-PAGE 
The urine samples were first purified by dialysis in order to remove salts and to adjust the 
pH. The dialysis was performed against dialysis buffer usually 1x PBS, using 10 kDa 
molecular weight cut-off (10K MWCO). 100 ml urine was dialysed against 1000 ml PBS. 
Dialysis was carried out for 24 hours at 4oC with 3 times. Subsequently urine sample were 
applied to immmunprecipitaion and Western blot.  
2.2.1.18 Measurement of the acidification in the urine samples 
Immunoprecipitation needs pH 7.3 because this increases antibody-antigen capture by 
protein G beads. Thus, acidification was determined utilizing cell debris-free urine for 
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estimating the pH value by the color change of the tracers in the urine and the pH-indicator 
strips pH 5.2-7.5 (Merck, Darmstadt, Germany). Urine was considered as acidified if the pH 
decreased below 7.0 and was adjusted using 10x PBS. 
2.2.1.19 Sample elution 
The sepharose beads which contain precipitated proteins were washed 3 times with precold 
PBS. Then, 100 µl of rehydration buffer 2 (Biorad) prepared by addition of 75 mM β-
mercaptoethanol was added, and incubated for 30 minutes at 5°C in a thermo-mixer rotating 
at 5 x g. After elution the beads were centrifuged for 2 minutes at 800 x g and the 
supernatant transfer into a new tube. Another 100 µl of rehydration buffer 3 which contained 
0.05% (w/v) DTT was added then incubated and centrifuged as before. The supernatant 
obtained were pooled for further analysis. 
2.2.1.20 Rehydration 
The PROTEAN Isoelectric focusing (IEF) cell with integrated power supply was used for 
rehydration and IEF protocols. The eluted protein samples were loaded onto IPG strips in 
IEF focusing tray for rehydration and first dimensional separation. IPG strip gels were placed 
side down in the channel of a focusing or rehydration tray that contains the sample in 
rehydration solution. For urine samples mostly 11 cm nonlinear IPG strips with 3-10 pH 
range were used. Strips were covered with 2 ml of mineral oil to prevent evaporation which 
causes the urea to precipitate as it becomes more concentrated. IPG strips with sample in a 
focusing tray were active rehydrated by running of IEF cell under low voltage as 50 volts 
overnight. 
2.2.1.21 First dimensional separation: Isoelectric focusing (IEF) 
After the strips have rehydrated the ends of each strip was lifted and wet electrode wicks 
were inserted between the strip and the electrodes. Strips were covered with mineral oil 
before starting the focusing run to prevent evaporation and carbon dioxide absorption during 
focusing. Isoelectric focusing was performed at voltage linearly increased from 150 to 5000 V 
during the first 5 hours, followed by 8000 V for a total of 70000 Vh/h 
Temperature 20˚C 
Current max. 0.05 mA per strip 
Sample volume 200 µl for 11 cm strip, 300 µl for 17 cm strip  
Step Voltage Time / Volt-hour 
1 150 V 30 minutes. rapid 
2 300 V 60 minutes. slow 
3 1000 V 60 minutes. slow 
4 1500 V 60 minutes. slow 
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5 2000 V 60 minutes. slow 
6 3000 V 60 minutes. slow 
7 5000 V 60 minutes. slow 
8 8000 V 4 hours slow 
9 8000 V 70000 Vh linear 
10 500 V 3 h linear 
Table 13: Applied voltage steps for IEF 
2.2.1.22 Equilibration 
This process reduces disulfide bonds and alkylates the resultant sulfhydryl groups of the 
cysteine residues. Rehydration/equilibration trays sized for each size strip were used for 
equilibration. Each strip was moved to equilibration tray and the channels were filled with the 
equilibration buffers. Strips were first incubated in DTT equilibration buffer-I that reduces 
sulphydryl groups for 15 minutes at room temperature, and then the channels were refilled 
with iodacetamide equilibration buffer-II which alkylates sulfhdryl groups and incubated for 15 
minutes at room temperature. For the strips with 11 cm length, 3 ml of each equilibration 
buffers were used. After equilibration, IPG strips were removed and embed into the prepared 
second-dimension gel. 
2.2.1.23 Second dimensional separation 
The second dimension electrophoresis of isoelectric focused proteins was carried out on pre-
casted polyacrylamide gels obtained from BioRad (Criterion Precast Gel 10% Tris-HCl, 1.0 
mm). The equilibrated IPG gel strips were placed on top of the polyacrylamide gel and 
overlaid with 2 ml 0.5% melted agarose prepared in SDS-PAGE running buffer. A small 
amount of Bromophenolblue was added to the agarose overlay to track the ion front during 
the run. The SDS gel running was performed with a voltage setting of 60 V for 15 minutes 
and then at 120 V until the end. BioRad Dodeca Cell which accommodates 12 gels per run 
was mostly used for proteomics analyses. To estimate the molecular mass of each spot, 
marker proteins were placed on a filter strip left to the strip on the gel. Polyacrylamide gels 
were stained with silver and/or Coomassie Brillant Blue (BioRad) according to the 
procedures described previously (Merril et al., 1981a). 
2.2.1.24 Protein detection 
To visualize proteins after separation in 2-DE gels it is necessary to use an adequate 
staining method. The enormous variation in characteristics and abundance of the individual 
proteins put high demands on the staining technique. The most important requirements are 
high sensitivity, high linear dynamic range, high reproducibility and compatibility with mass 
spectrometry. Major developments of protein staining methods have occurred during the last 
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few years. Since silver staining is the most sensitive non-radioactive detection technique and 
the costs for reagents are relatively low when compared to fluorescence techniques, it is still 
widely used. There are presently more than 100 different modifications of the original silver 
staining protocol that was introduced by (Merril et al., 1981a). In this study silver staining, 
coomassie blue staining Western blotting methods were used to visualize the protein spots. 
2.2.1.25 Concentration of urinary proteins by acetone precipitation 
Acetone precipitation was performed on urine sample to precipitate proteins present in the 
urine. 400 µl of urine was transferred into a 2 ml microcentifuge tube containing 1.4 ml pre-
chilled acetone. The samples were mixed by vortexing, and incubated overnight at -20°C. 
The precipitates were obtained after centrifugation 10 minutes at 18620 x g. Then the pellets 
were air dried. However the pellet was not completely dried to allow resuspension complete. 
Subsequently, the pellet was resuspended in 100 µl PBS and stored at -20°C until further 
use. 
2.2.1.26 Concentration of urinary proteins via centricon columns 
Urine sample of 2 ml volume was applied onto a Centrifugal Filter Column (Amicon) to 
remove molecules smaller than 5 kDa such as urea, electrolytes, and salts and to increase 
the protein concentration of the urine samples. The sample was centrifuged at the speed of 
800 x g at 4°C. The pass through was discarded while the up portion kept for further analysis 
on gel electrophoresis. 
2.2.1.27 Separation of hydrophilic and hydrophobic fractions via ultracentrifugation 
Ultracentrifugation allows elimination of membrane vesicles and cell granules by extremely 
high speed.  A volume of 10 ml urine samples was collected and centrifuged at 4000 x g for 
10 minutes to removes any cells debris in it. Subsequently, a fraction of 1.5 ml was 
transferred into an Eppendorf tube and labeled as “before ultracentrifugation”. The rest of the 
fraction was transferred into ultracentrifugation tubes.  
Alternatively, 20 ml of cell culture supernatant from different cell lines were collected and 
centrifuged at 4000 x g for 5 minutes to removes any cells debris. Then, 8 ml were 
transferred into different tubes and labeled as “before ultracentrifugation” this contained both 
the hydrophilic as well as hydrophobic fractions. Concurrently, we transferred 9 ml in 
ultracentrifugation tubes. The samples in the ultracentrifugation tube were then centrifuged at 
41823 x g in a Sorvall SA-600 rotor (Thermo Scientific) for 2 hours at 4°C. Thereafter 1 ml of 
urine sample and 8 ml of cell culture supernatant was carefully transferred into fresh tubes. 
All sample fractions were then analyzed by ELISA and immunorecipitation using the protocol 
described above. 
2 Materials and Methods 
46 
2.2.1.28 Phase separation assays 
10 ml of Triton X-114 was transferred into a 50 ml tube, and 40 ml of 1x PBS containing a 
drop of Bromophenol blue was added. The tube was mixed well by vortexing and rested at 
room temperature for 1 hour. Then, the tubes were centrifuged at 4000 x g for 30 minutes 
keeping without break gradient to avoid destruction also to separate the lipophilix TX-fraction 
with hydrophilic fraction. The PBS was carefully sucked off. 500 µl of concentrated Triton X-
100 was transferred into a tube containing same volume of cell debris-free urine. Then, the 
sample was mixed by vortexing and incubated under permanent rotation at room 
temperature for 1 hour. Afterwards the tube was centrifuged at 4000 g for 5 minutes .The 
upper hydrophilic and lower hydrophobic fractions were transferred into different tubes. The 
concentration of CEACAM1 in each fraction was analyzed by sandwich ELISA. 
2.2.1.29 Sucrose gradient separation 
Cells were incubated with 1 ml DMEM medium having 10 µg/ml of anti-CEACAM1 
monoclonal antibody (18/20) for different time intervals from 5 minutes, 15 minutes, 30 
minutes, 45 minutes, and 1 hour. As control no mouse antibody was applied to the samples. 
The samples were lysed in 200 µl PIRA buffer utilizing the protein extraction protocol 
(3.2.1.1). The gradient was formed by layering from the bottom to the top of a 10 ml tube 1 
ml each of  48%, 35%, 25%, 17%, 10%, and 1% sucrose (sucrose was diluted with PIRA 
buffer). This gradient was overlaid with 200 µl of cell lysate. Samples were then centrifuged 
at 235000 x g in a type 45 Ti rotor (Beckmann) for 18 hours at 4oC. After centrifugation, 
sample fractions of 516 µl each were carefully collected from top to bottom. Fractions were 
separated by 9 % Tricine gels electrophoresis. 
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2.2.2 Immmunological methods 
2.2.2.1 Solid phase ELISA -Enzyme-linked immunosorbent assay 
This type of ELISA the antigen is directly immobilized to the ELISA plate. 
1. Antigen: 100 µl of appropriate sample was added into NUNC-Immuno plate (Thermo 
fischer scientific Roskilde, Denmark) and incubated for atleast 2 hours at room 
temperature or alternatively at 4°C overnight. Usually urine samples were diluted 1:2 
with 1.5% blocking buffer, cell lysate 1:50 and supernatants were not diluted. After 
incubation the sample was flipped off, and then 300 µl of blocking buffer (3% BSA-
PBS) was added. Then incubated the plate for 1-2 hours at room temperature then 
followed by washing steps. The washing was done by filling the wells with 150 µl of 
PBS and flicking the washes out.  
2. Detection antibody: Then the plate was incubated with 100 µl anti-CEACAM1 
monoclonal antibody (10 µg/ml) diluted in 1.5% BSA-PBS for 2-4 hours at  room 
temperature or overnight at 4oC followed by washing steps. For biotinylation assay 
the plate was incubated with 100 µl biotin-coupled anti-CEACAM1 monoclonal 
antibody (10 µg/ml) diluted in 1.5% BSA-PBS. 
3. Labeling: After, washing the plate was incubated with 100 µl horseradish peroxidase-
conjugated goat anti-mouse IgG diluted in 1.5% blocking buffer. The plate was then 
washed and completely dried by flipping the plate before the substrate was added. 
4. Substrate: Enzymatic reaction was developed by adding 150 µl of TMB substrate 
(Sigma) and the reaction product stopped after 15-30 minutes by addition of 20 µl of 
2M H2SO4. Absorbance at 450 nm was measured in a microplate reader (Tecan 
Germany). The standard curve and blank were run in each plate to ensure accuracy 
and for accurate quantitative results were always compared with the signal of 
samples against those of standard curve.  
This ELISA technique is cheap and fast although it has some limitations associated with 
sensitivity, specificity and accuracy due to the factors concerning the binding of antigen to 
the solid matrix. These can be greatly increased by the use of another type of ELISA 
referred to as sandwich ELISA. 
2.2.2.2 Sandwich ELISA 
This type of ELISA is more specific and sensitive than the solid phase ELISA because the 
antigen is measure between two antibodies referred to as capture and detecting antibodies, 
which can be either monoclonal or polyclonal. The technique is also more accurate and if 
purified antigen standard is available, the assay can determine the absolute amount of 
antigen in an unknown sample. 
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Figure 6: A cartoon illustrating Sandwich ELISA. 
The antigen is sandwich between the capture antibody on the bottom of the plate and the 
detection antibody. 
 
In our studies it was performed as follows:  
1. Capture antibody: NUNC-Immuno plate (Thermo fischer scientific Roskilde, Denmark) 
was coated overnight at 4oC with 5 µg/ml of the capturing antibody polyclonal rabbit 
anti-human carcinoembryonic antigen (DAKO) or with monoclonal antibody B3 diluted 
in PBS. After incubation capture antibody solution was removed by flicking the plate 
over a sink. Then the plate was blocked with 300 µl of blocking buffer (3% BSA in 
PBS) for 1-2 hours at room temperature followed by washing steps. The washing was 
done by filling the wells with 150 µl of PBS and flicking the washes out.  
2. Antigen: Then, 100 µl of appropriate sample was added and incubated the plate for 
atleast 2 hours at room temperature or alternatively at 4°C overnight. Usually urine 
samples were diluted 1:2 with 1.5% blocking buffer, cell lysate 1:50 and supernatants 
were not diluted. Afterwards the plate was washed three times with 150 µl of PBS 
3.  Detection antibody: Then the plate was incubated with 100 µl anti-CEACAM1 
monoclonal antibody (10 µg/ml) diluted in 1.5% BSA-PBS for 2-4 hours at room 
temperature or overnight at 4oC followed by washing steps.  For biotinylation assay 
the plate was incubated with 100 µl biotin-coupled anti-CEACAM1 monoclonal 
antibody (10 µg/ml) diluted in 1.5% BSA-PBS.  
4. Labeling: After washing, the plate was incubated with 100 µl horseradish peroxidase–
conjugated goat anti-mouse IgG diluted 1:5000 in 1.5% blocking buffer. The plate 
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was then washed and completely dried by flipping the plate before the substrate was 
added.  
5. Substrate: Enzymatic reaction was developed by adding 150 µl of TMB substrate 
(Sigma) and the reaction product stopped after 15-30 minutes by addition of 20 µl of 
2M H2SO4. Absorbance at 450 nm was measured in a microplate reader (Tecan 
Germany). The standard curve and blank were run in each plate to ensure accuracy 
and for accurate quantitative results were always compared with the signal of 
samples against those of standard curve. 
2.2.2.3 Detection of CEACAM1 expression by flow cytometry 
To analyze the surface expression of CEACAM1 in different cell types flow cytometry 
analysis was performed. Adherent cells were collected by the EDTA-Typsin method (3.2.1.1) 
while PMN were directly utilized to FACS procedure. Up to 0.5 x106 cells, were incubated 
with CEACAM1 monoclonal antibody 18/20 (10 µg/ml) in FACS buffer (PBS with 3% FCS) for 
1 hour on ice. The cells were washed 3 times with 300 µl of FACS buffer, vortexed gently 
and centrifuged by 250 x g for 3 minutes at 4o C. The wash buffer was removed by flipping 
the tube once and touching a soft filter paper. Then, the cells were incubated for 30 minutes 
with 100 µl of secondary flourescein isothiocynate (FITC) conjugated antibody diluted 1:50 in 
FASC buffer. For negative controls cells were stained with secondary FITC antibody or with 
isotype matched control immunoglobulin. This was followed by washing steps. Cells were 
resuspended in 200 µl of FACS buffer prior to measurement. The samples were measured 
using a FASC calibur instrument (Becton Dickison) and the data were analyzed by Cell 
Quest software (Becton Dickison).  
2.2.2.4 Absolute quantification of CEACAM1 on cell surfaces by flow cytometry 
Flow cytometric quantification of the CEACAM1 expression was performed using DAKO 
QIFIKITR kit. The kit contains a series of beads, 10 µm in diameter and coated with different 
well-defined quantities of mouse monoclonal molecules (high-affinity anti-human CD5, Clone 
ST1, isotype IgG2a). The beads mimic cells with different antigen densities which have been 
labeled with primary mouse monoclonal antibodies, isotype IgG. The cells were stained with 
excess amount of monoclonal antibody 18/20 (10 µg/ml) diluted in FACS buffer. Negative 
controls were included of cells only stained with secondary FITC antibody. The samples were 
incubated on ice for 1 hour. 10 µl each of Set-Up Beads and Calibration beads were 
transferred into fresh tubes. Then, samples were washed 3 times with 300 µl of FACS buffer, 
vortexed gently and centrifuged by 250 x g for 3 minutes at 4oC. The wash buffer was 
removed by flipping the tube once. Then, 100 µl of FITC conjugate diluted 1:50 in FACS 
buffer was, gently vortexed and incubated for additional 30 minutes on ice in the dark. After 
incubation the tubes were washed 3 times as described above.  200 µl of FACS buffer was 
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added for cytometry measurements. Set-Up Beads were used for the establishment of 
window of analysis and the fluorescence analysis was confirmed to the beads singled clear 
of debris as defined on a forward scatter versus side scatter dot blot. Without changing the 
analysis window the calibration beads and the samples were analyzed. The mean number of 
monoclonal antibodies molecules bound to cells was the calculated from the net mean 
fluorescence intensity by the use of the linear relation furnished by the standard curve. 
2.2.2.5 Determination of apoptosis 
 
Apoptosis (“programmed” cells death) is a physiological process by which unwanted cells are 
eliminated during development and other physiology processes. Apoptosis is defined by 
various characteristics changes such as cell shrinkage, increased cytoplasmic density, DNA 
fragmentation and formation of apoptotic bodies that contain nucleic or cytoplasmic material. 
One of the events in apoptosis is the DNA fragments of approximately 185 bp (Wyllie et al., 
1980). This cellular event can be analyzed by agarose gel electrophoresis which measures 
DNA fragmentation in nuclear extracts showing a typical DNA ladder shear (Compton and 
Cidlowski, 1986). Other improved methods visualize the DNA after Southern blotting with 
radiolabelled probes (Facchinetti et al., 1991) and 32P-labeled nucleic acid (Rosl, 1992). 
These techniques have several disadvantages; they are time consuming, requires a great 
number of cells, involves radioactivity in some more sensitive assays, and they are unable to 
determine the percentage of apoptotic cells or recognize the apoptotic cells in a 
heterogeneous cell population. DNA fragmentations can also be measured by fluoresces 
microscope after staining with a DNA-binding dye. This method is simple but it is not easy to 
discriminate between early and late apoptotic cells 
To distinguish between early and late apoptosis flow cytometric analysis based on double-
staining for Propidium Iodide (PI) and flourescein isothiocynanate (FITC) conjugated Annexin 
V can be used. An early event in apoptosis is rapid alternation in the organization of 
phospholipids leading to the flipping of the phosphatidyl serine (PS) from the inside surface 
to the out side surface of the plasma membrane. Annexin V-FITC can be used as 
flourenscent probe to label apoptotic cells. Annexin V binds to exposed PS, which appears in 
the outer leaflet of the plasma membrane in early apoptotic cells. The binding of Annexin V is 
calcium dependant process. 
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Figure 7: A cartoon representation of phospholipid flipping during apoptosis. 
The picture shows the inversion of phosphatidylserine (PS) after induction of apoptosis and 
subsequent biding of Annexin V to the cell surface under well-difined cacium concentration 
(A and B). Obtained from www.bdbiosciences.com. 
 
In the late apoptotic cells, the plasma membrane becomes permeable and allows uptake of 
PI, which intercalates into DNA. Thus, PI in conjunction with Annexin V-FITC staining allows 
discrimination between viable, early and late apoptotic cells as follows: 
Viable cells 
 Negative to Annexin V-FITC 
 Negative to Propidium Iodide 
Early apoptotic cells 
 Positive to Annexin V-FITC 
 Negative to Propidium Iodide 
Late apoptotic/ Dead cells 
 Positive to Annexin V-FITC 
 Positive to Propidium Iodide 
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Figure 8: Representative dot plots of Annexin V-FITC/PI analysed flow cytometry. 
A modified dot plot flow cytometic analysis of Jurket cells induced with camptothecin 
overnight at 37o C, stained with Annexin V-FITC and PI (From Cellular analysis business 
center, USA). 
 
To determine apoptosis from different cell types flow cytometric analysis was performed after 
staining the cells using Annexin V-FITC and PI. Cells were cultured in presence and absence 
of following apoptosis inducers: actinomycin (30 µM), camptothecin (6 µM), cycloheximide 
(300 µM), dexamethasone (30 µM), etoposide (30 µM), and Fas-Ligand (0.2 µg/ml) for 24 
hours. Old medium was replaced and the cells washed with PBS. Then, 1 ml DMEM which 
contained apoptosis inducer was transferred into the cells. A control was included in which 
apoptosis was not induced. Then the plate was incubated in the cell culture incubator for 24 
hours. Up to 0.5 x106 cells were, incubated for 30 minutes in 50 µl DMEM containing 
Annexin-V FITC at concentration of 1:390. The cells were washed 3 times with 300 µl FACS 
buffer and centrifuged at 250 x g for 3 minutes.  Then, DMEM containing PI at 1:120 
concentrations was added and immediately the cells were analyzed by flow cytometry in a 
FASC Calbur instrument using Cell Quest software (Becton Dickison). A fraction of these 
cells were lysated and further analyzed by Western blot to compare CEACAM1 before and 
after apoptosis. 
2.2.2.6 Leukocyte cells isolation 
Human peripheral blood mononuclear cells (PBMC) and neutrophilic granulocytes 
[polymophonuclear neutrophils (PMN)] were isolated as follows 
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A total volume of around 40 ml of whole blood from healthy donors was collected in a tube 
containing NH2-Heparin (Sarstedt-Monovette). The blood was transferred into 50 ml tube 
under sterile condition. Then 1 ml of 6% dextran in DMEM was added into the blood, shaken 
gently to mix well and the air bubbles were removed my opening the lid then closing it 
immediately. Then sample was incubated for 45 minutes at room temperature to sediment 
erythrocytes. After sedimentation, the plasma was transferred into a fresh tube, centrifuged 
at 710 x g (centrifuge ROTINA 38 from Hettich zetrifugen, Germany) for 10 minutes at room 
temperature to pellet leukocytes. In case the solution was not clear 10 ml of 1x PBS was 
added and then centrifuged again as described above. The serum which does not contain 
blood cell and clotting factors was discarded while the pellet resuspended in DMEM medium. 
The leukocytes suspension was carefully layered onto a Ficoll-paque (GE Heathcare) which 
have density gradient of 1.075-1.077 g/ml. The sample was centrifuged at room temperature 
first at 710 x g for 3 minutes then the speed was increased to 1610 x g for 27 minutes without 
break. This resulted into two layers, the upper whitish layer of PBMC and PMN pellet 
containing some erythrocytes on the bottom of the tube.  After centrifugation, the DMEM 
medium was removed and PBMC cells were transferred into a new tube. Then the Ficoll-
paque was sucked off and the PMN pellet was gently mixed in 2 ml steril (Osmo-schock) H20 
for 20 seconds to lyze the remaining erythrocytes. The tube was filled up to 45 ml with 
DMEM medium. This step was repeated until all erythrocytes were lyzed. For the PBMC 
fraction the Ficoll-paque was completely removed by adding DMEM medium up to a volume 
for 45 ml. Both samples were centrifuged at 250 x g for 5 minutes at room temperature. 
PBMC and PMN cells were resuspended in 2 ml 10% FCS DMEM medium. The cells were 
counted. The purity of both cell fractions was verified by flow cytometric analysis of the 
granularity of the cells analyzing the side scatter (SSC). 
2.2.2.7 Culturing and stimulation of PBMC 
PBMC cells were isolated from blood of healthy donors by dextran sedimentation followed by 
Ficoll-paque as described above. Approximately 2 x 106 cells were transferred into three 
flasks having 1.5 ml culture medium containing phytohemagglutinin- PHA (Roche Diagnotics) 
(0.005 µg), anti-CD3 monoclonal antibodies(1 µg/ml) and anti-CD28 monoclonal antibodies 
(1 µg/ml). The samples were pipetted up and down to mix. As control a flask of non-
stimulated PBMC cells was also included. Then, the flasks were incubated at 37oC incubator 
overnight. In some assays stimulation kinetics was determined at different time points. After 
incubation, the stimulation was monitored by flow cytometric analysis. All samples were then 
analyzed by Western blotting using the protocol described previously. 
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2.2.2.8 Human monocytes differentiation to macrophages  
Human peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by 
dextran sedimentation followed by density gradient centrifugation using Ficoll-paque as 
described previously. Macrophages  were obtained by culturing approximately 5 x106 PBMC 
cells in 10 ml DMEM medium containing 10 ng/ml of Granulocyte macrophage colony-
stimulation factor (GM-CSF) and interleukin-3 receptor (IL-3 a colony stimulating factor) for 7 
days. As control PBMC cells were cultured in absence of stimulating factors. 
2.2.2.9 Co-Culture of macrophages and PMN 
Cell undergoing apoptosis are usually recognized and swiftly ingested by macrophages. The 
clearance of apoptotic or senescent PMN by macrophages is a crucial process in events 
such as homeostasis, wound healing and tissue regeneration. To prevent damage of the 
surrounding tissues, PMN undergo apoptosis (Haslett, 1992) which leads to recognition and 
phagocytosis by macrophages. Inappropriate clearance of apoptotic cells may lead to 
autoimmune diseases and chronic inflammation (Rosen and Casciola-Rosen, 1999). Thus 
phagocytosis actively down-regulate inflammatory and immune responses further insuring 
safe clearance of apoptotic cells and unwanted proteins. 
To determine what happens to CEACAM1 expressed on PMN, the PMN cells were co-
cultured with macrophages. PMN cells were freshly isolated from heparinize blood of healthy 
donors by dextran sedimentation followed by Ficoll-paque as described previously. The 
mononuclear cells isolated by centrifugation on Ficoll-paque density gradient then 
differentiated to macrophages as described above. A flask having differentiated 
macrophages was taken and its supernatant transferred into fresh tube for future analysis. 
The flask was thoroughly washed with 1x PBS to remove undifferentiated monocytes. Then, 
the macrophages cells were overlaid with 10 ml DMEM media containing 20 x106 of freshly 
isolated PMN cells. As controls one flask was cultured with only macrophages and another 
with PMN cells only. Then, the flasks were incubated at 37 °C incubator for 24 hours. After 
the incubation, the cells and their supernatants were subjected to Western blotting as 
previously described. 
2.2.2.10 Spontaneous apoptosis in PMN 
Freshly isolated PMN were divided into two fractions each having 20 X106 cells. One portion 
was transferred in to an Eppendorf tube, pelleted down then frozen at -200C until further use. 
The rest of the cells were transferred in to a flask containing 10 ml DMEM medium. The flask 
was cultured in a cell incubator for 24 hours. Thereafter, the cells and supernatant were 
separately collected and further analyzed. 
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2.2.3 Protein and cell surface labelling 
2.2.3.1 RotiR-MagBeads COOH (ROTH) kit 
The matrix of Roth–MagBeads-COOH consist of uniform superparamagnetic silica beads 
coated with surface carboxyls (-COOH) functional groups. The beads are of magnetic iron 
oxide with an average size of 1 µM. Protein binding was performed via functional amine 
groups. The beads were coupled with different concentrations of anti-CEACAM1 monoclonal 
antibodies 1-200 µg per 1 ml (3-4 X109 beads / ml) of magnetic beads. The coupling was 
carried out according to manufacturer’s instructions. All washing steps of beads were done 
via magnetic field. To monitor coupling efficiency the protein contain in reaction utilized 
protein determination methods (Bradford, BCA assay) was analyzed. The efficiency of 
coupling beads was also determined by Sandwich ELISA and flow cytometry before their use 
in immnunoprecipitations. 
2.2.3.2 MagnaBindTM Carboxyl Derivatised Beads (PIERCE) Kit 
MagnaBindTM beads can be used for affinity chromatography procedures to purify specific 
molecules from a complex mixture. The beads were supplied as aqueous suspension of 
magnetic iron oxide beads coated with carboxyl groups for covalent coupling of molecules 
using EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbiimide hydrochloride). EDC is a 
crosslinker that is reactive to amine and carboxyl functional groups. 1 ml of beads was 
washed with 1 ml PBS to remove storage buffer. In our studies anti- CEACAM1 monoclonal 
antibodies were diluted in conjugation buffer containing MES (N-Morholinoethane sulfonic 
acid) into different concentrations (1-200 µg) and transferred into the washed beads. The 
coupling was performed according to manufactures instructions. 
2.2.3.3 MagnaBindTM Amine derived beads. 
The coupling of anti-CEACAM1 monoclonal antibodies was done according to the 
manufacturer’s instructions. In short, 1 ml of beads was coupled with 2.5-10 mg/ml of anti-
CEACAM1 monoclonal antibodies using BS3 as chemical cross linker.  BS3 (5 Mm) was 
dissolved in PBS. The sample was incubation for 30 minutes at room temperature for 
coupling reaction. Then, the coupling reaction was stopped by addition of stop buffer (1 M 
Tris Ph 7.5). The quality of coupled beads was analyzed by sandwich ELISA and flow 
cytometry before they were used for immunoprecipitation. 
2.2.3.4 Biotinylation assays 
Biotin is a vitamin found in minute amount in every living cell. Biotin is a small molecule (244 
dalton) by which it can be introduced to proteins, in most cased without significant altering 
their biological activities. In most cases proteins or cell molecules are biotinylated via amine 
fuctional groups by using biotinylation reagents N-hydroxysuccinimide (NHS) esters and N-
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hydrosulfosuccinimide (sulfo-NHS) esters. In our biotinylation the following reaction was 
preformed 
 
Figure 9: Chemical reaction illustration of protein biotinylation. 
Obtained from Avidin-Biotin technical handbook –Thermo Scientific/ Pierce. 
 
The cells were washed two times with PBS, followed by three washing with PBS which 
contains CaCl2 (0.0901 mM) and MgCl2 (0.493 mM) (Gibco). The cells were incubated for 1 
hour on ice by gentle shaking in presence and absence of 0.5 mg/ml PBS-Biotin (EZ-link -
Sulfo-NHS-LC-Biotin from Pierce) solution. After incubation, the cells were washed 3 times 
with PBS which contained CaCl2 and MgCl2 to remove any free biotin. The cells were 
washed with 0.05 M Glycine-PBS buffer to block any free amines. Then, the cells were 
washed three times with PBS to wash way blocking buffer. 1 ml of DMEM-FCS cell culture 
medium was added and the samples were incubated at 37oC for different time intervals. As 
positive control one well was biotinylated, immediately scrapped off. As negative control one 
well was not biotinylated. At the end of incubation time the cell and supernatants were 
collected, analyzed by Western blot as previously described.  
2.2.3.5 Affinity Purification of biotinylated proteins 
Streptavidin is a biotin binding protein that is isolated from Streptomyces avidini and has 
molecular mass of 60 kDa. The interaction between streptavidin and biotin is characterized 
by the formation of high affinity interaction. This high affinity ensures that once formed, it will 
not be disturbed by changes in pH, or processes such as multiple washings. Immobilized 
streptavidin on agarose beads can be used to purify biotinylated cell surface receptors. 
The cells and supernatants from biotinylated samples were collected by transferring the cell 
culture into fresh tube and centrifuging it at 4000 x g for 10 minutes to pellet down the dead 
cells. Then free-cell culture supernatant was transferred in to a new tube. The samples were 
lysed in 200 µl PIRA buffer utilizing the protein extraction protocol (3.2.1.1) and transferred 
into fresh tube. In both tubes 60 µl of streptavidin Agarose beads were added and incubated 
at 4oC on a rotator overnight. Next beads were centrifuged at 800 x g for 1 minute, and 
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supernatant was discarded. 500 µl of PBS was added to wash the beads, and centrifuged at 
800 x g for 1 minute, washing step repeated twice. The beads were resuspened in 60 µl 2.5x 
Laemli sample buffer containing 75 mM β-mercaptoethanol and boiled at 98oC for 10 
minutes. The eluted proteins were separated via 11% tricine gel electrophoresis and 
detected by Western blot.  
2.2.3.6 Quantification of biotinylation 
To determine the efficiency and quantity of biotinylation the cells were stained using CyTM3-
conjugated streptavidin (Jackson ImmunoResearch) and analyzed by flow cytometry. From a 
6 well plate one well was biotinylated with 0.5 mg/ml and another well with 1 mg/ml to 
determine which concentration of biotin is required for optimal biotinylation. Unbiotinylated 
cells served as control was. The cells were washed two times with PBS, followed by three 
washing with PBS which contains CaCl2 (0.0901 mM) and MgCl2 (0.493 mM) (Gibco). The 
cells were incubated for 1 hour on ice by gentle shaking in presence and absence PBS-Biotin 
(EZ-link -Sulfo-NHS-LC-Biotin from Pierce) solution. After incubation, the cells were washed 
3 times with PBS which contained CaCl2 and MgCl2 to remove any free biotin. The cells were 
washed with 0.05 M Glycine-PBS buffer to block any free amines. Then, the cells were 
washed three times with PBS to wash way blocking buffer. Immediately after washing the 
cells were removed by trpsin-EDTA treatment. 10 µl of biotinylated and unbiotinylated 
samples were transferred into a FACS tube having 100 µl FACS buffer which contained 
Streptavidin-Cy3 washing (1:40). As negative control no Streptavidin-Cy3 staining was done. 
To determine apoptotic cells, the samples were stained in 200 µl FACS buffer containing PI 
diluted 1:200 from a stock concentration of 1 mg/ml. The staining was verified by flow 
cytometric analysis. 
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2.2.4 Cell biological methods 
General cell culture work was performed under sterile conditions under a laminar flow hood 
using disposable plastic ware. 
2.2.4.1 Culturing 
Cell lines (Table 6) were placed in polystyrene culture flasks 25 cm2 (T25) and 75 cm2 (T75) 
(Falcon) provided with 0.2 µm hydrophobic vent caps and maintained in a humidified 5% 
CO2 atmosphere in an incubator (Hera Cell 240) at 37°C. Glass wares were sterilized by 
heating at 180°C for 8 hours. For sub-culturing adherent cells were cultured until sub-
confluence of 70-90%. Medium was removed and cells were washed with pre-warm PBS. 
The cells were incubated with 1.5 ml trypsin-EDTA for 3-5 minutes at 37°C. Subsequently, 
the cells were transferred to a tube containing a double volume of culture medium to block 
the trysin. Cells were pelleted harvested by centrifugation at 250 x g for 3 minutes at room 
temperature. The supernatant was removed and cells were washed with cell culture medium. 
The cells were diluted approximately 1:10 with fresh medium and seeded into new culture 
flask. 
2.2.4.2 Freezing and thawing of cells 
Adherent cells were removed from the flask by 0.05% trypsin-EDTA treatment. 5 x106 cells 
were transferred to a tube, pelleted at 250 x g for 3 minutes and supernatant was completely 
removed. The cells were then resuspended in 1.8 ml serum-free freezing medium. 
Immediately the cells were transferred into prelabelled freezing tubes and stored at -80oC for 
one month. Thereafter, cells were transferred into liquid nitrogen for long-time storage. 
Cryopreserved cells were thawn rapidly. Using a Pasteur pipette a few drops of pre-warmed 
cell culture medium were added into the tube and pipetted up and down for the cells to thaw 
and mix. Using the same pipette the thawed cells were immediately transferred into a tube 
containing 8 ml of warm cell culture media. Then the cells were centrifuged at 250 x g for 3 
minutes at room temperature. After removal of the medium the cells were resuspended in 1 
ml of media culture and transferred into a flask containing 10 ml cell culture medium. The 
flask was then placed into 370C incubator. 
2.2.4.3 Determination of cell number 
A cell suspension diluted 1: 100 with 1x PBS was used for determination of cell number. With 
a cover slip in place 10 µl of diluted cells were mounted in a Neubauer chamber (Assistant, 
Germany). 
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Figure 10: A drawing showing the squares on the Neubauer chamber. 
This is obtained from www. Biochem.northwestern.edu/protocols. 
 
The cell number could be calculated after counting cells in all four quadrants of the chamber, 
each containing sixteen smaller squares, with the following equation: 
Number of cells/ml = average count per square x the dilution factor x 104. 
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2.2.5 Molecular biological methods 
2.2.5.1 Isolation of total RNA 
Total RNA from cells were isolated using QIAGEN RNeasy mini kit. To avoid RNAse 
contamination, disposable plastic ware and RNAse-free water was used. The cells were 
trypnized and a fraction of 2 X106 cells were taken for RNA isolation. The cells were 
transferred into an Eppendorf tube centrifuged at 250 x g for 3 minutes at room temperature, 
then supernatant was aspirated. The centrifugation was repeated to completely remove the 
remaining medium. The cell pellet was rescuspended in 350 µl of RT Buffer which contained 
β-mercaptoethanol at a ratio of 1:100 for lyzing by pipetting up and down for at least 15-20 
times. The cell lysates were stored at -20oC or directly RNA isolation was performed. The 
frozen cell lysates were thawn on ice and passed at least 20 times through a blunt 20-gauge 
needle of 0.9 mm diameter fitted to an RNase free syringe. The rest of the protocol was done 
according to manufactures instructions. DNAse treatment was done was then performed by 
on-column DNase digestion using the same kit. The RNA was eluted using 50 µl RNase-free 
water. Usually the concentration of RNA is determined by measuring the absorbance at 
260nm (A260) in a spectrophotometer. RNA has its absorbance at 260 nm and the ratio of 
absorbance at 260 and 280 nm is used to assess the RNA purity. Pure RNA has an 
A260/280 ratio of 1.8-2.1. For determination of RNA concentration an absorbance of 1 unit at 
260 nm is equivalent to about 40 µg/ml (A260 = 1 = 40 µg/ml). This is valid only when the 
sample is in water. The concentration is calculated using the below formulae: 
 
Concentration of RNA sample= 40 x A260 (OD) x dilution factor. 
 
However, in our studies RNA concentration was determined by measuring the absorbance at 
260 nm using Label Guard TM Microliter Cell (Implen, Germany) in a biophotometer 
(Eppendorf, Germany).  The instrument uses two lids one having 1 mm (factor 10) and 
another with 0.2 mm (factor 50) and this offer an automatic dilution factor of 1/10 and 1/50. 3 
µl of undiluted sample was transferred directly on to the measuring device, and then followed 
by placing the one of the lid. The measurement is calculated automatically in 10-15 seconds 
using above formulae. 
2.2.5.2 Reverse transcription 
1µg total RNA was reverse transcribed using QIAGEN-QuantiTect Reverse Transcription. 
DNA contamination was first cleansed using genomic DNA wipeout buffer supplied with the 
kit. The rest of the protocol was done according to manufactures instructions. 
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2.2.5.3 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR), a procedure for rapid in vitro enzymatic amplification of a 
specific segment of DNA, was used for the amplification of cDNA encoding CEACAM1.The 
template cDNA was dilute 1:5 with RNase-free water. For amplification of cDNA, 5 µl of 
diluted of reverse transcription product was added to 25 µl master mix (Table 14) with 
primers as described below. Vector pcDNA 3.1 containing CEACAM1 was used as positive 
control whereas water was used as negative control Glyceraldehyde-3-phosphate (GAPDH) 
served as a housekeeping gene to ensure equivalent DNA loading. The reaction conditions 
for CEACAM1 and GAPDH are shown in table below. 
 
                                         Components          Volume-1x 
 
        Template                                           5 µl 
   dNTP´s                                              0.6 µl 
   10x PCR Buffer                                  3 µl     
   Forward Primers                                3 µl 
   Reverse Primers               3 µl 
   Taq DNA polymerase               0.2 µl 
 
   Total volume (per probe)              30 µl 
Table 14: Composition of PCR reaction. 
 
Specific primers annealing to CEACAM1 used for PCR reaction were purchased from MWG 
Operon (Germany) while the dNTP´s, 10x buffer and the Taq polymerase were purchased 
from GeneCraft. The primers for CEACAM1 and GAPDH were designated as show in Table 
below. 
 
               
       Primer Name                                     Primer sequences 
CEACAM1 all 
Sence   AAC AGC GGT CGA GAG ACA AT  
Antisense  CTC CAC AGG GTT GGA GTT GT 
GAPDH                                              
Sense   TGA TGA CAT CAA GAA GGT GG 
Antisense  TTT CTT ACT CCT TGG AGG CC 
             
             Table 15: Name and sequences of the primers used in this study. 
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For amplification of CEACAM1 and GAPDH cDNA 35 cycles and 29 cycles were used 
respectively. 
 
 
                           Step                        Temperature [°C]            Time  
 
       Initial denaturation  95              3 Minutes 
   CEACAM1: 35 Cycles 
                        GAPDH:    29 Cycles    
   Denaturation             95   30 Seconds 
   Primer annealing  60   20 Seconds 
   Elongation   72   30 Seconds 
   Extension    72              8   Minutes 
                        Cooling                                 4                                  Forever 
Table 16: PCR conditions for CEACAM1 amplification 
 
The reactions were performed in PCR plate (Biozym), using a PCR iCycler (BioRad). The 
GAPDH was used as control reaction. The PCR products were analyzed on a 2% agarose 
gel and visualized by SYBR Safe DNA gel staining (Invitrogen)  
2.2.5.4 Agarose gel electrophoresis 
The PCR product was electrophoretically separated on 2% (w/v) agarose gel prepared in 
TAE buffer containing 50X SYBR Safe DNA gel staining. 1x TAE buffer was used as running 
buffer. 10 µl samples were mixed with 2 µl 6x loading buffer, and then placed 11 µl of it onto 
the pockets gel. 5 µl of DNA molecular marker (Fermentas) was loaded into one pocket to be 
used for sample size evaluation. The DNA was visualized on an UV transilluminator at 302 
nm and documented by a gel documentation instrument (Intas Gel Imager). For equal 
loading of CEACAM1 PCR product bands were judged in comparison with the GAPDH 
control gel. 
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3. The aims of the study 
 
Previous studies have reported the presence of soluble CEA in human urine. However, the 
presence of CEACAM1 was neglected (Draberova et al., 2000), until most recently our group 
reported the presence of soluble CEACAM1 in urine of patients suffering bladder cancer 
(Tilki et al., 2009). However, the soluble CEACAM1 found in urine was not sufficiently 
investigated so far. Therefore, the tasks of this doctoral thesis were to identify the cellular 
origin and glycosylation stutus of CEACAM1 found in urine. In addition, to investigate which 
isoform or domain structure of CEACAM1 is present in urine. Furthermore, we wanted to 
investigate the mechanism leading to generation and secretion of this CEACAM1 form. 
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4. Results 
4.1 Characterization of soluble CEACAM1 in urine 
4.1.1 Determination of CEACAM1 and CEACAM5 in human urine 
We first quatified the levels of CEACAM1 and CEA (CEACAM5) concentrations in healthy 
individuals using sandwich ELISA we recently developed. Our results showed concentration 
of 7 ng/ml ± 5 ng/ml (n=12) for CEA (Figure 11 left panel). This result agreed very well with 
the CEA concentration known from the literature (Guinan et al., 1974). Surprisingly, 
CEACAM1 concentration was much higher having 200 ng/ml ± 110 ng/ml (n=16) (Figure 11 
right panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Determination of the CEA and CEACAM1 level in human urine. The 
concentration of CEA and CEACAM1 in urine was determined by sandwich ELISA. A 
polyclonal CEA antibody was coated on the wells of an ELISA plate. The captured molecules 
were detected using monocloconal antibodies specific for CEA and CEACAM1 respectively 
as described in the method section. The absorbance was read at 450 nm. 
4.1.2 Urine CEACAM1 variant at 72 kDa  
Depending on the cell type the molecular weight of CEACAM1 can be at 120-160 kDa due to 
differences in glycosylation (Kannicht et al., 1999; Lucka et al., 2005). For example, 
CEACAM1 on PMNs cells have a molecular weight of 160 kDa (Lucka et al., 2005) whereas 
epithelial and endothelial cells have 120 kDa and 140 kDa respectively (Bamberger et al., 
1998; Prall et al., 1996). However, due to the protein marker we used in this study 
sometimes the molecular weight was higher or lower. Therefore, we decided to use 120 kDa 
to represent full length CEACAM1.  
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In order to further verify, the presence of CEACAM1 in urine and to determine its molecular 
weight immunoprecipitation was performed. The immunoprecipitated samples were analyzed 
by Western blot and detected using an anti-CEACAM1 monospecific antibody. As positive 
control HeLa-CEACAM1-4L cell lysates was included. In parallel Western blot analyses were 
performed for detection of CEA from human urine and from HeLa-CEA cell lysates as 
positive control. Then blots were detected using anti-CEA monoclonal antibody. Western 
blots showed the expected molecular weight of CEA (180 kDa) in HeLa-CEA cell lysates as 
well as in urine. In addition, 120 kDa of the known molecular size of CEACAM1 was detected 
in the HeLa-CEACAM1 probe. However, in urine a band below 75 kDa was detected (Figure 
12). Calculation utilizing protein standard revealed a molecular weight of 72 kDa for the 
CEACAM1 found in urine. This band was most recently reported (Tilki et al., 2009) by our 
group and it was stated to represent a soluble CEACAM1 variant. However, nothing about 
the biochemical set up and its origin was shown yet. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 12: Detection of CEACAM1 and CEA expressed by transfected HeLa cell in 
comparison with those found in urine.  
Immunoblot analysis was performed as described in method part. The experiment shown is 
representative of three different experiments. 
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4.1.3 Soluble and membrane bound CEACAM1 in human urine samples  
To determine whether CEACAM1 found in urine represents the soluble or the membrane-
anchored form, TX-114 based phase separation assay was performed. The separated 
fractions were subsequently analyzed by sandwich ELISA to quantify amount of CEACAM1 
in each fraction (Figure 13A). The concentration of CEACAM1 in this cohort of healthy 
donors was 100 ng/ml ± 10 ng/ml (n=4) in the control urine prior to the separation into a 
hydrophilic and a hydrophobic fractions. After the phase separating centrifugation the 
hydrophilic fraction contained 70 ng/ml ± 5 ng/ml (n=4) whereas the hydrophobic fraction 
contained only 10 ng/ml ± 5 ng/ml (n=4). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Characterization of soluble CEACAM1 found in urine.  
A) Urine sample was collected and subjected to phase separation assay using Triton X-114. 
Subsequently, each fraction obtained was analyzed by sandwich ELISA for determination of 
the CEACAM1 concentration. B) Urine sample was collected and subjected to 
ultracentrifugation for two hours and the upper layer transferred for further analysis. Then the 
sample together with a control of native urine was analyzed for the determination of 
CEACAM1 concentration using sandwich ELISA. The experiments shown are representative 
data of three different experiments.  
 
 
To confirm the results gained with phase separation assay, ultracentrifugation of the urine 
samples followed by sandwich ELISA was performed. For that urine samples were taken and 
divided into two portions. One was kept untreated as control urine while the other portion was 
subjected to the ultracentrifugation step. After ultracentrifugation the upper layer was 
carefully transferred into a new tube without disturbing the pellet. Then both the control urine 
and the ultracentrifugated portion were analyzed by sandwich ELISA to determine the 
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concentration of CEACAM1. As shown (Figure 13B) 80 ng/ml ± 5 ng/ml (n=4) were water 
soluble which equal to 88.9% whereas 10 ng/ml ± 2 ng/ml (n=4) were membrane bound. 
Thus leads to conclude that the main CEACAM1 fraction in urine is soluble and not 
membrane bound. 
4.1.4 Reduced molecular weight of urine CEACAM1 and its glycosylation. 
The extracellular domains of CEACAM1 are heavily glycosylated, generally more than half of 
the molecular weight of CEACAM1 consists of carbohydrate (Lucka et al., 2005). Thus, it 
was tempting to hypothesize that the molecular weight differences are caused by differences 
in gylcosylation. To analyze this idea we performed deglycosylation assays. A control assay 
of deglycosylated human CEACAM1-Fc construct was utilized to first determine the exact 
molecular weight of a deglycosylated CEACAM1. As shown in (Figure 14A) the size of the 
undeglycosylated human CEACAM1-Fc was approximately 120 kDa whereas following 
complete deglycosylation the size reduced to approximately 75 kDa. Although the CEACAM1 
in human urine was only a little bit smaller compared with the deglycosylated CEACAM1-4, it 
could have been the answer. But deglycosylation of CEACAM1 isolated from urine revealed 
a band of molecular 40 kDa. (Figure 14A right panel). Thus CEACAM1 in urine is still highly 
glycosylated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 14: Deglycosylation studies of CEACAM1.  
A) Deglycosylation assay was performed as described in the method part. B) Western blot 
analysis of CEA and CEACAM1 from feces for comparison with degylcosylation assay. 
These are representative data of three separate experiments. 
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In addition the concentration of CEA in feces was determined using sandwich ELISA and 
found to be approximately 1 mg/ml (data not shown) which corresponded well with what was 
previously reported (Elias et al., 1974). Feces samples were analyzed by Western blot for 
CEA and CEACAM1 (Figure 14B). Detection of CEA in feces showed a broad band at 
approximately 180 kDa and additional faint bands at 75 kDa, 50 kDa, 45 kDa, and at 40 kDa. 
On the other hand, detection of CEACAM1 showed only one broad band at 40 kDa which 
corresponds to that of deglycosylated CEACAM1 in urine. 
4.1.5 Urine CEACAM1 without N-Domain. 
To determine whether the decrease in molecular weight of CEACAM1 in urine may be 
caused by changes in the number of CEACAM1 domains epitope mapping using sandwich 
ELISA was performed. This was done by applying different monoclonal antibodies binding to 
distinct epitopes at different CEACAM1 domains. The detecting antibodies used were 
specifically binding to the various domains as follows: 18/20, R+D (N-domain), B3 (A1 
domain), C5-1X (B domain) 4D1/C2 (the linker between B-A2 domains), 8G5 (A2 domain) 
and anti-CEACAM1 cyto (cytoplasmic region). The signal intensity of Hela-CEACAM1-4L 
(control) in total cell lysates was determined by optical density (OD) and taken as 100%. 
Then the amount of CEACAM1 detected in the urine sample was calculated as percentage of 
the positive control detected by the same antibody. As shown (Figure 15A) CEACAM1 was 
not detected by both antibodies that bind to the N-domain. Also the monoclonal antibody 
specific for the A2 domain and the cytoplasmic region of CEACAM1 were negative. In 
contrast, the antibody that binds to the A1-domain and another that binds the linker between 
B and A2- domains were strongly positive. 
To confirm that urine CEACAM1 does not have N-domain, a part of the A2 and the entire 
cytoplasmic region, urine samples were subjected to ultracentrifugation with subsequent 
epitope mapping using the different antibodies as described above. Detection of CEACAM1 
using monoclonal antibody that binds to A1B domains showed that hydrophilic fraction 
contained 90% ± 5% CEACAM1 whereas the hydrophobic contained only 10% ± 5% (Figure 
15B). The optical density of each fraction was calculated as percentage of the 100% total 
urine. CEACAM1 was not detected by monoclonal antibodies that binds to the N-domain A2 
domain and the cytoplasmic region (data not shown). The results indicated that CEACAM1 in 
urine does not have the N-domain, part of A2-domain and the cytoplasmic region. Thus, in 
this study the 120 kDa CEACAM1 was referred to as full length while the 72 kDa CEACAM1 
variant was termed as truncated CEACAM1. 
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Figure 15: Epitope mapping of CEACAM1 in urine.  
A) The plate was coated with polyclonal anti-CEA antibody and the captured CEACAM1 
molecules were detected using different monoclonal antibodies specific for distinct epitope as 
described above. The amount of CEACAM1 bound was measured in absorbance at 450 nm. 
It was measured in triplicates. HeLa-CEACAM1 cell lysates was used as positive control for 
the monoclonal antibody. B) Urine sample was subjected to ultracentrifugation and domains 
recognized in each fraction were quantified by sandwish ELISA. A control of total urine was 
included. Then the optical densities obtained were calculated in percentages in relation to 
control. These are representative data of three separate experiments. 
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4.2 Characterization of CEACAM1 in human granulocytes  
4.2.1 Expression of full length but not truncated CEACAM1 in human granulocytes 
It is well known that human granulocytes (PMN) express high amounts of CEACAM1 with a 
molecular weight of 160 kDa molecular weight (Drzeniek et al., 1991). In order to identify 
whether granulocytes could be the likely source of the 72 kDa soluble CEACAM1 found in 
urine Western blot analysis were preformed. CEACAM1 was detected using two distinct 
mouse monoclonal antibodies 18/20 (binding to the N-domain) and 4D1/C2 (binding to the 
liker between A1 and B domains). As shown (Figure 16) both antibodies detected only the 
described full length CEACAM1 with a molecular weight of 160 kDa but not the truncated 
CEACAM1. These results confirm the expression of CEACAM1 on granulocytes and show 
that no truncated CEACAM1 was identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Identification of CEACAM1 expressed in human granulocytes.  
Western blot analysis of CEACAM1 from whole lysates of human granulocytes was done as 
described in the method part using antibodies directed against CEACAM1. The results 
shown are representative of three independent experiments. 
  
4.2.2 No detection of truncated CEACAM1 in human granulocytes under 
spontaneous or ligand induced apoptosis  
Normally, granulocytes are short-lived cells with a half-life of only 6-20 hours in the 
circulation, after which they undergo constitutive (spontaneous) apoptosis. Previous studies 
reported that healthy donors produce and destroy 180 x 107 granulocytes per day (Haslett et 
al., 1991; ATHENS et al., 1961). Thus, we wanted to analyze whether truncated CEACAM1 
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may appear in granulocytes due to spontaneous apoptosis. PMNs cells freshly isolated were 
either kept or cultured for 24 hours as described in the method part. The whole cell lysates of 
the freshly isolated control, PMNs cells after 24 hours and their cell culture supernatant were 
collected and analyzed by Western blot. The results showed 160 kDa bands representing full 
length CEACAM1 in both fresh isolated and apoptotic granulocytes (Figure 17A). A minor 
band of 160 kDa was detected in the cell culture supernatant indicating minimal release of 
full length CEACAM1 due to apoptosis. If this released form appeared due to shedding or 
due to microvesicles (MV) was not analyzed in this work. Flow cytometric analysis after 
staining the cells with Annexin V-FITC and propidium iodide confirmed spontaneous 
apoptosis (data not shown). There was no 72 kDa band detected in any of the sample 
indicating that truncated CEACAM1 is not generated due to spontaneous apoptosis of 
granulocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Effect of CEACAM1 found in granulocytes due to spontaneous and Fas-
ligand induced apoptosis.  
A) Western blot analysis of cell lysates and cell culture supernatant obtained before and after 
spontaneous apoptosis. B) Western blot analysis of cell lysates and cell culture supernatant 
before and after Fas-Ligand induced apoptosis. All blots were developed using monospecific 
anti-CEACAM1 antibody. These are representative data of three separate experiments. 
 
The expression of Fas receptors on the surface of granulocytes as reported (Liles et al., 
1996) implicated the possibility the granulocytes initiate a death pathway at the cell surface. 
To test whether the truncated CEACAM1 may appear due to Fas ligand induced apoptosis 
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freshly isolated PMN were cultured in the presence and absence of soluble Fas ligand. The 
whole cell lysates of a control of freshly isolated granulocytes, FasL-induced sample, and its 
cell culture supernatant were analyzed for CEACAM1 expression by Western blot. The 
results showed 160 kDa bands representing the full length CEACAM1 in both freshly isolated 
as well as apoptotic granulocytes (Figure 17B). A weak band with 160 kDa was also detected 
in the cell culture supernatant indicating minor release of full length CEACAM1. Flow 
cytometric analysis of Annexin V-FITC/propidium iodide staining confirmed FasL-induced 
apoptosis (data not shown). There was no 72 kDa band detectable in any of the samples 
indicating that in granulocytes truncated CEACAM1 is also not generated by ligand-induced 
apoptosis.  
4.2.3  No association of truncated CEACAM1 to PMN ingestion by macrophages 
Usually apoptotic or senescent granulocytes are cleared using phagocytosis by 
macrophages. To determine whether, the truncated CEACAM1 might appear due to 
ingestion of granulocytes by macrophages freshly isolated PMNs were co-cultured with 
macrophages as described in the method part. Then all samples fractions were analyzed by 
Western blot analysis. As shown (Figure 18) a 160 kDa band of full length CEACAM1 could 
be detected in lane 1, 2 and 5 which originated from freshly isolated PMNs, cultured PMNs, 
and suspension cells of macrophages in presence of PMN respectively. Very faint bands of 
full length CEACAM1 could be detected in cell culture supernatants of PMNs confirming a 
minimal release of full length CEACAM1 after spontaneous apoptosis and in the adherent 
cells of macrophages in presence of PMN. This may be due to the already attached PMN cell 
on the macrophages. However, no band was detected in the supernatant of the 
macrophages in presence of PMN cells, adherent macrophages, also in macrophages in 
suspension and in supernatants of macrophages. Furthermore, in none of the samples the 
72 kDa band of the truncated CEACAM1 was found. Lack of any detectable CEACAM1 in 
the cell culture supernatant of the macrophages in presence of PMNs suggest that 
CEACAM1 on granulocytes was completely digested by macrophages. These results 
demonstrated clearly that truncated CEACAM1 found in the urine does not result from 
ingestion of granulocytes by macrophages.  
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Figure 18: CEACAM1 expression in granulocytes co-incubated with macrophages. 
Western blot analysis of whole cell lysates and supernatant from granulocytes and 
macrophages not incubated and co-incubated with macrophages was performed applying 
CEACAM1 monospecific antibody. The rest was done as described in the method part. The 
findings shown are representative of three independent different experiments.  
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4.3 Characterization of CEACAM1 in epithelial cells 
4.3.1 Epithelial cells as a potential source of truncated CEACAM1 
In order to further investigate the putative origin of the truncated CEACAM1 found in human 
urine the following epithelial cell lines known to express CEACAM1 endogenously (A549, 
HT29, and T102/3,) and stable transfected CEACAM1-4L cell line (HeLa-CEACAM1-4L) 
were cultured as described in the method part. Immunoprecipitation was performed on the 
whole cell extracts using monoclonal antibody 4D1/C2. Detection using the monoclonal 
antibody 18/20 that binds to the N-domain of CEACAM1 revealed a 120 kDa band of full 
length CEACAM1 in all cell types analyzed (Figure 19A). Interestingly, detection using the 
monoclonal antibody 4D1/C2 resulted in two bands; one at 120 kDa and another one at 72 
kDa in each of the cell line (Figure 19B). These results confirmed the presence of full length 
CEACAM1 and identified a 72 KDa CEACAM1 in epithelial cell which was not detected by 
the N-Domain binding antibody 18/20. Thus, epithelial cell are very likely to be the source of 
truncated CEACAM1.  
 
 
 
  
 
 
 
 
 
 
 
 
Figure 19: Expression of both full length and truncated CEACAM1 in different cells 
lines   
Immunoprecipitation and Immunoblot of whole cell lysates from A549, T102/3, HT29 and 
CEACAM1 transfected HeLa cells (HeLa-CEACAM1-4L) was performed as described in the 
method part. Anti CEACAM1, which binds to N-domain showed full length CEACAM1 
whereas antibody binding to the linker between B-A2 domains showed that truncated 
CEACAM1 is additionally expressed in these cell lines. These are representative data of 
three separate experiments. 
 
4.3.2 The appearance of 72 kDa CEACAM1 and glycosylation 
Having identified various epithelial cell lines as well as transfectants as putative source for 
the truncated CEACAM1, we further characterized this 72 kDa CEACAM1 form. 
Deglycosylation assay was performed to determine whether the decrease of CEACAM1 from 
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120 kDa to 72 kDa may appear due to differences in glycosylation. Immunoprecipitation 
experiments were carried out utilizing monoclonal antibody B3 followed by Western blot 
using non-glycosylated and deglycosylated samples (Figure 20). As shown in the A549 cells 
sample (lane 1) both 120 kDa and 72 KDa of non-deglycosylated CEACAM1 were 
detectable. However, after treatment with PNGase enzyme resulted in weak bands at 75 kDa 
and at 40 kDa representing the non-deglycosylated CEACAM1 of 120 kDa and 72 KDa 
respectively. In T102/3 samples (lane 2) the main band appeared at 120 kDa and additional 
fainter band at approximately 72. However, no band was detected for deglycosylated 
CEACAM1. Finally in HT29 cells both 120 kDa and 72 kDa were detected whereas following 
degylcosylation only a 40 kDa band was detected. These results clearly show that 
deglycosylation of 120 kDa and 72 kDa leads to 75 kDa and 40 kDa bands respectively. 
Furthermore, the decrease of 72 kDa to 40 kDa corresponds well with the deglycosylation 
assay of soluble CEACAM1 in urine. The 72 kDa CEACAM1 variant found in urine is still 
glycosylated. Thus deglycosylation of CEACAM1 resulting in a decrease of the molecular 
weight from 140 kDa to 75 KDa can not be counted as the source of the 72 kDa CEACAM1 
variant. Interestingly, it was noted after degylcosylation the affinity to the antibody was very 
low thus resulting to faints band and this may suggest that sugars are of important in the 
binding of the antibody. 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 20: Characterization of non-deglycosylated and deglycosylated CEACAM1 
expressed in epithelial cells. 
Deglycosylation assay was performed using PNGase F enzyme treatment on 
immunoprecipited CEACAM1. Subsequently, the samples were analyzed by Western blot 
and detected by a monoclonal anti-CEACAM1 antibody. The experiment was repeated twice. 
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4.3.3 Truncated CEACAM1 expressed in epithelial cells lacks the N-domain 
To determine whether the 72 kDa CEACAM1 variant found in epithelial cells lacks the N-
domain further characterization using epitope mapping was performed. Immunoprecipitation 
of CEACAM1 from A549 cells with antibody specific for A1-B domains and another one 
specific for B-A2 domains was performed as described in the method part. Furthermore, 
detection using an antibody 4D1/C2 binding to the B-A2 domains recognizes both bands 
(Figure 21 right panel). However, detection using an antibody 18/20 binding to the N-domain 
recognizes only the full length at 120 kDa but not the 72 kDa (Figure 21 left panel). This 
experiment was also performed using T102/3 and HT29 and showed similar results (data not 
shown).These results clearly proofs that the 72 kDa form of CEACAM1 expressed in the 
epithelial cells lacks the N-domain. In line with the epitope mapping of soluble CEACAM1 
found in urine it clearly indicates that the 72 kDa form is a truncated variant of CEACAM1 
which does not have the N-domain, a part of A2-domain and the cytoplasmic region.  
 
 
  
 
 
 
 
 
 
 
 
 
Figure 21: Epitope mapping of lower molecular CEACAM1 expressed by A549 cells. 
Determination of epitopes was performed by immunoprecipitation with two distinct 
monoclonal antibodies that binds at A1-B and B-A2 domains respectively. Then recognition 
of the precipitated CEACAM1 was determined by Western blot using two antibodies, one for 
the N-domain, one for the A1-B domains. The experiment shown is representative of three 
different experiments.  
 
4.3.4 Appearance of truncated CEACAM1 and apoptosis 
It was previously reported that induction of apoptosis by various agencies leads to cleavage 
of CEACAM1 (Nittka et al., 2008). This results in a 58 kDa and a 14 kDa fragment. Thus, it 
was obvious to speculate that the truncated CEACAM1 found in the urine may appear due to 
apoptosis as well. To analyze that idea we utilized our cell lines and induced apoptosis using 
actinomycin, campthecin, cycloheximide, dexamethasone and etoposide. Then we controlled 
the apoptosis by Annexin V-FITC/PI staining and FACS analysis. Because all apoptose 
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inducing agents had almost similar results in this study we only show the results of 
actinomycin. The results showed that 75% ± 5% cell survival for the controls whereas only 
5% ± 3% survived in the case of induced cells. As shown (Figure 22 A and B) we could 
induce cell death significantly. Subsequent analyses of the expressed CEACAM1 revealed a 
full length but not truncated CEACAM1 (Figure 22 C). In the contrast to the published work of 
Nittka et al, neither 58 kDa nor 14 kDa CEACAM1 fragment could be detected. This 
experiment was also performed for other epithelial cells (data not shown) to eliminate the risk 
of failure. Therefore, apoptosis did not lead to the truncated CEACAM1.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Induction of apoptosis in A549 cells.  
A/B) Apoptosis was induced in the cells for 24 hours as described in the method part. Then, 
the samples were stained with Annexin V-FITC and PI and analyzed by flow cytometry. B) 
Shows statistics of 5% ± 3% (n=3) cell death after induced apoptosis. The results indicate 
percentages of cell survival which are the mean ± SD (error bars). C) Western blot of living 
and apoptotic A549 cells with respect to the CEACAM1 expression. The data shown are 
representative of three different experiments.  
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4.3.5 Appearance of truncated CEACAM1 and down regulation of epithelial 
CEACAM1  
The results that A549 cells down regulated CEACAM1 when entering into the proliferative 
state (Singer et al., 2010) led to the idea that truncated CEACAM1 might result due to this 
process. They also reported that A549 cells that had just reached confluence did not express 
CEACAM1. However, these cells induced and therefore increased the CEACAM1 expression 
as soon they entered the post-confluent growth arrest state. This in mind, confluent cells 
which showed high CEACAM1 expression were seeded into culture vessels with low cell 
density and named as day 0 cells. Initially, absolute CEACAM1 expression on the surface of 
these cells was analyzed by quantitative flow cytometric analysis (data not shown). The data 
agrees with those published recently (Singer et al., 2010). The cells were constantly cultured 
in proliferating growth phase for one, two, three, four, and seven days, respectively. Then, 
the whole cell lysates were collected and analyzed by Western blot (Figure 23A). On day 0 
(Figure 23A) a main band of CEACAM1 appeared at 140 kDa accompanied by a band at 72 
kDa. One day later (day 1) the expression of full length CEACAM1 slightly decreased 
whereas truncated CEACAM1 slightly increased. The following day (day 2), the expression of 
both full length and truncated CEACAM1 started to decrease, and continued to decrease 
until very little expression of full length CEACAM1 was detectable and no truncated 
CEACAM1 was left. To investigate the increase of truncated CEACAM1 between day 0 and 
day 1 the same assay was repeated but rather for short time periods (1, 2, 4, 6, 8 and 24 
hours). Results did not show any significant increase of truncated CEACAM1 (data not 
shown). 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 23: Reduced CEACAM1 expression in cells entering proliferation.  
A) Western blot of confluent and log phase cultured A549 cell lysates was done as described 
in the method part. The detection of beta-actin served as loading control. B) The released 
CEACAM1 from confluent and log phase cultured A549 cells was quantified by sandwich 
ELISA as described in the method part. The values ± SD were determined from triplicates. 
The data shown are representative of four different experiments.   
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This data showed that the decrease of surface CEACAM1 does not lead to the increase of 
truncated form of CEACAM1. To further analyze whether the down-regulated CEACAM1 
may have been shed and secreted into the cell culture supernatant, sandwich ELISA was 
performed (Figure 23B n=4). The results showed very little amount (0.1 ± 0.03 OD) of 
CEACAM1 released in cell culture supernatant on day 0, whereas nearly nothing was 
measurable at a later time point. According to these results the truncated CEACAM1 is not 
associated with reduced CEACAM1 expression in cells entering proliferation. However, the 
loss of both full length and truncated CEACAM1 during cell proliferation implies that the cells 
may need all amino acids and sugar of the degraded CEACAM1. 
We next quantified CEACAM1 expression in cell growth phases of epithelial cell using 
quantitative flow cytometry approach was used. The cells were cultured with low density, for 
at least two days to be in log phase prior to analysis. To reach tight confluency, cells were 
cultured for additional six days after reaching confluency. The cells were stained with 
monoclonal antibody 18/20 and the level of CEACAM1 expression was determined in 
reference to calibration beads conjugated with a known amount of antigen for secondary 
antibody. In log phase of HT29 and T102/3 cells a significant expression of approximately 
8,000 ± 1500 (n=4) molecules per cell was observed where as in case of A549 cells no 
CEACAM1 expression on the surface of was detected. However, a signification up-regulation 
with approximately 18,000 ± 4000 (n=4) molecules per cell was observed when all cell types 
were kept in confluency (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Characterization of the cell surface expression of CEACAM1 in different 
growth stages.  
Epithelial cells were collected from different cell growth stages as indicated, were then 
analyzed by absolute quantitative flow cytometry utilizing the QuiFiKit approach as described 
in the method part. The values ± SD were determined from triplicates. These data are 
representative of four separate experiments. 
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4.3.6 Appearance of truncated CEACAM1 and turnover in epithelial cells  
Having known that A549 cells that had reached confluence did not express CEACAM1 but 
the expression increased as cell entered the post-confluent contact inhibited growth stage. 
This led us to investigate whether, the increase of CEACAM1 expression during post-
confluent phase would lead to appearance of truncated CEACAM1. Epithelial cell lines 
(A549, T102/3, HT29) were seeded as described in the method part. Protein extracts were 
collected when confluent, confluent plus one week, confluent plus two weeks, and confluent 
plus three weeks. Western blot analysis of A549 cells using monoclonal antibodies 18/20, 
C5-1X and 4D1/C2 detected little CEACAM1 expression in lysates of just confluent cells 
(Figure 25A). As shown (Figure 25A left panel) detection using the monoclonal antibody 
(18/20) specific for the N-domain of CEACAM1 detected an increase in the expression of the 
full length CEACAM1 in the confluent plus one week sample. This increase continued when 
the cells were kept in contact inhibited state for confluent plus two weeks, and confluent plus 
three weeks, respectively. As shown (Figure 25A middle panel) when the blots were detected 
using the monoclonal antibody C5-1X expression of both full length and truncated CEACAM1 
increased as cells were kept in a contact inhibited state. Interestingly, a significant increase 
of truncated CEACAM1 could be observed by the not N-domain binding monoclonal antibody 
4D1/C2 (Figure 25A right panel) when cells were grown from confluent to confluent up to 
three weeks. The results shown above were confirmed using T102/3 cells (Figure 25B) and 
HT29 cells (Figure 25C). We found that monoclonal antibody 4D1/C2 detected broad bands 
of truncated CEACAM1 and faint bands of full length CEACAM1 whereas, C5-1X detected 
broad bands of full length CEACAM1 and faint bands of truncated CEACAM1 although both 
monoclonal antibodies were not CEACAM1 N-domain binding. These differences may be 
due to the antibodies affinities or accessibility of their distinct epitopes. The presence of full 
length CEACAM1 but not truncated CEACAM1 when using monoclonal antibody 18/20 
confirmed that the truncated CEACAM1 does not contain N-domain. These results 
demonstrated that both full length as well as truncated CEACAM1 appeared and significantly 
increased when the cells were kept in contact inhibited state. Thus, the molecular protein 
turnover seemed to play an important role in expression and regulation both full length and 
truncated CEACAM1. 
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Figure 25: Up regulation of full length and truncated CEACAM1 in contact-inhibited 
epithelial cells.  
A) A549 cells, B) T102/3 cells, C) HT29 cells were cultured for indicated time intervals. 
Whole cell lysates were collected after the cell growth stages as indicated above. 
Subsequently, samples were analyzed by Western blot and the determination of CEACAM1 
was done using three distinct monoclonal anti-CEACAM1 antibodies. The detection of beta-
actin served as loading control. The data shown are representative of three different 
experiments. 
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These results were expanded by absolute quantitative flow cytometric analysis of cell surface 
CEACAM1. The CEACAM1 expression was analyzed as cells were just confluent, confluent 
plus one week, confluent plus two weeks, and confluent plus three weeks (Figure 26). The 
results showed low expression of CEACAM1 in just confluent cells. However, the expression 
progressively increased attaining approximately 25,000 ± 2,200 (n=3), 41,000 ± 5,030 (n=3), 
and 22,000 ± 1,850 (n=3) molecules per cell in A549, T102/3 and HT29 cells, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Characterization of the cell surface expression of CEACAM1 in contact 
inhibited resting cells.  
Epithelial cells were collected from different cell growth stages as indicated, were then 
analyzed by absolute quantitative flow cytometry using the QuiFiKit approach as described in 
the method part. The values ± SD were determined from triplicates. These are representative 
data of three separate experiments. 
 
4.3.7 Both full length and truncated CEACAM1 are released into the cell culture 
supernatant of long term cultured epithelial cells 
To determine whether the increased full length and truncated CEACAM1 corresponds with 
the secreted amount into the cell culture supernatant sandwich ELISA was performed (Figure 
27A). The results showed that a very small amount of CEACAM1 was released into the cell 
culture supernatant of just confluent A549, T102/3 and HT29 cells. However, a significant 
amount was detectable in confluent plus one week cells. This increased higher in confluent 
plus two weeks sample. Confluent plus three weeks sample were also analyzed and showed 
a significant higher amount of CEACAM1 (data not shown). These results showed a 
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continuous increase of released CEACAM1. To confirm this result immunoprecipitation of the 
cell culture supernatants was performed (Figure 27B). As shown in figure 15b no band was 
detected in the cell culture supernatant of just confluent A549 cell whereas to a minor extent, 
full length as well as truncated CEACAM1 was detected into the cell culture supernatant of 
confluent T102/3 and HT29 cells. Furthermore, an increasing amount of both full length and 
truncated CEACAM1 was detected in the cell culture supernatant of confluent plus one week 
and confluent plus two weeks in all three epithelial cell lines. These results showed that full 
length as well as truncated CEACAM1 are released and significantly increased when the 
cells were kept in contact inhibited state.  
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Figure 27: Determination of soluble CEACAM1 released from contact inhibited 
epithelial cells. 
A) For quantification of CEACAM1 released from contact-inhibited epithelial cells, samples 
were analyzed by sandwich ELISA as described in the methods section. The values ± SD 
were determined from triplicates. B) Immunoblot analysis for the presence of CEACAM1 
released from culture contact-inhibited epithelial cells was done as described in the method 
section. These are representative data of three separate experiments. 
 
4.3.8 No detection of truncated CEACAM1 on the cell surface 
To determine whether truncated CEACAM1 is found on the cell surface, biotinylation assay 
was performed as described in the method part. An aliquot of the cells were examined for the 
efficiency of biotinylation by flow cytometry analysis. A control of unbiotinylated cells, and 
biotinylated cells (0,5 mg/ml and 1 mg/ml) were stained with Cy3-conjugated streptavidin. 
The measurement showed no staining for the unbiotinylated cells (control) whereas cells 
biotinylated with 0,5 mg/ml and 1 mg/ml showed a positive reaction median of 3162 and 
3751 relative fluorescence, respectively (Figure 28A). 
The remaining aliquot of cells were lysed, biotinylated molecules were isolated by affinity 
purification using streptavidin agarose beads and then subjected to Western blot analysis 
(Figure 28B). The results using monoclonal antibody 4D1/C2 detected only 120 kDa of full 
length CEACAM1 but not truncated CEACAM1 in both biotinylated samples. This shows that 
72kDa truncated CEACAM1 variant was not biotinylated and thus not present on the cell 
surface. This experiment was also performed using T102/3 and HT29 and showed similar 
results (data not shown). 
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Figure 28: Presence of full length but not truncated CEACAM1 on the cell surface.  
A) Cells were biotinylated as described in the method part. Then, they were stained with 
CyTM3-conjugated streptavidin and analyzed by flow cytometry analysis. A control of 
unbiotinylated cells was included. B) To identify cell surface CEACAM1, biotinylated cells 
were lysed, and subjected to affinity purification using streptavidin agarose beads. 
Subsequently, the precipitated proteins were analyzed by Western blot using monospecific 
antibody not against the N-domain of CEACAM1. The data shown are representative of three 
separate experiments. 
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4.3.9 Internalization of full length CEACAM1 and appearance of truncated CEACAM1 
in turnover processes 
Following our results we hypothesized that the full length CEACAM1 would be internalized, 
and the N-domain and part of the A2 domain together with the cytoplasmic region would be 
completely digested by e.g. proteases. The remaining part forms the truncated 72 kDa 
CEACAM1 which accumulates in the cell and finally becomes secreted. To analyze this idea 
we performed internalization assays on the A549 cells as described in the method part. In 
principle biotinylation of cell surface receptors allows the examination of receptor 
internalization, secretion and sometimes recycling process. In this assays, cell surface 
proteins were first biotinylated on ice. After the removal of the biotin solution and the 
blockage of unreacted sites, cells were transferred at 37 °C to allow endocytosis of 
biotinylated CEACAM1. As controls, some cells were not biotinylated while others were 
biotinylated but not transferred to 37 °C. In line with our hypothesis only CEACAM1 receptors 
on the surface and those that were internalized as truncated CEACAM1 during 37 °C 
incubation period remained biotinylated. The biotinylated proteins were isolated with 
streptavidin agarose beads and CEACAM1 was detected by Western blotting. Our results 
showed that after 15, 30, 45, and 60 minutes only biotinylated full length CEACAM1 was 
detectable (Figure 29A). Further increase of internalization time for one hour, three hours, 
five hours and eight hours respectively produced the similar results that only biotinylated full 
length CEACAM1 was detectable (Figure 29B). However, when the internalization was 
increased further the Western blot (Figure 29C) showed a continuous decrease in the 
amount of biotinylated full length CEACAM1 from day 1, day 2, day 3 and day 4 respectively. 
In addition, a faint band of truncated CEACAM1 was detected on day 1. One day later (day 
2) the amount of truncated CEACAM1 slightly decreased and this continued on day 3 until 
nothing was detected on day 4. These results demonstrate that the truncated 72 kDa 
CEACAM1 variant could results from endocytosis of full length CEACAM1. This because 
previous results demonstrated clearly that truncated CEACAM1 is not localized on the cell 
surface.  
To determine whether the disappearance of both biotinylated full length and truncated 
CEACAM1 could result in secretion into the cell culture supernatant, affinity purification using 
strepvidin agarose beads was performed. Interestingly, no biotinylated CEACAM1 was 
detected in the supernatant (data not shown). This may suggest that once full length 
CEACAM1 was internalized, truncated CEACAM1 was generated, but almost immediately 
protease enzymes within the cell could cleave the biotin, resulting in not biotinylated 
CEACAM1 in the cell culture supernatant.  
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Figure 29: Internalization of full length CEACAM1 and generation of the truncated 
CEACAM1 variant.  
A549 cell were biotinylated with biotin as described in the method section. A) Western blot of 
biotinylated CEACAM1 after biotin treatment and subsequent culturing for 15 minutes, 30 
minutes, 45 minutes, and 1 hour. B) Western blot of biotinylated CEACAM1 after biotin 
treatment and subsequent culturing for 1 hour, 3 hours, 5 hours and 7 hours. C) Western blot 
of biotinylated CEACAM1 after biotin treatment and subsequent culturing for 1 day, 2 days, 3 
days, and 4 days. Controls of unbiotinylated cells and biotinylated but cultured were included 
in all experiments. The data shown are representative of three separate experiments. 
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4.3.10 Regulation of CEACAM1 at the transcription level 
Previous results showed an increase of both full length and truncated CEACAM1 in the 
whole cell lysates of the contacted inhibited epithelial cells. In addition, quantitative analysis 
of surface CEACAM1 using flow cytometry showed a progressive up-regulation. Total RNA 
was isolated from the contact inhibited A549 cells to determine whether, CEACAM1 mRNA 
expression was similar to what was observed with the total protein and the surface 
expression or whether there were some alterations. Subsequently the mRNA was analyzed 
by PCR as described in the method section. The primers were designed specific to all 
CEACAM1 isoforms but with no exon so that only CEACAM1 mRNA would be amplified. 
GAPDH RNA expression was determined as an internal control to optimize the loading 
between each time point. The results showed low expression of CEACAM1 mRNA in sparse 
cells (Figure 30 line 5). Interestingly, a significant expression of CEACAM1 mRNA was 
observed in just confluent cells (Figure 30 line 1). However, no further change of the 
CEACAM1 mRNA expression was observed when the cells were kept in contact inhibited 
state for confluent plus one week, confluent plus two weeks, and confluent plus three weeks, 
respectively. (Figure 30 line 2, 3, and 4). The expression remained at the same level when 
cells were grown from confluent to confluent up to three weeks. This experiment was also 
performed using T102/3 and HT29 and showed similar results (data not shown). These 
results demonstrate that CEACAM1 is regulated at the translation but not at the transcription 
level.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 30: PCR analysis of the CEACAM1 mRNA levels in A549 cells in contact 
inhibited state.  
Vector pcDNA 3.1 containing CEACAM1 and another containing GAPDH were used as 
positive controls whereas water was used as negative control. The data shown are 
representative of three separate experiments. 
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4.4 Characterization of the 95 kDa CEACAM1 variant found in endothelial cells 
4.4.1 Analysis of endothelial cells as putative source of truncated CEACAM1 
To determine whether endothelial cells could be a further origin of truncated CEACAM1 we 
analyzed the AS-M.5 an established cortex endothelial cell line. Detection using monoclonal 
antibodies 18/20 and C5-1X showed 160 kDa bands representing the full length CEACAM1 
(Figure 31 left and middle panels). In addition, C5-1X detected a very faint band at 95 kDa. 
However, detection using monoclonal antibody 4D1/C2 revealed a clear band at 95 kDa and 
additional faint band of 160 kDa (Figure 31 right panel). A549 cells were included because 
we found that they express both full length and truncated CEACAM1. These results identified 
a 95 kDa CEACAM1 variant in endothelial cells which was not detected by an N-domain 
binding antibody. Thus endothelial cells could be a further source of truncated CEACAM1 
found in the urine.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Generation of different variant of truncated CEACAM1 by endothelia versus 
epithelia. Immunoblot analysis of whole cell lysates from AS-M.5 was performed as 
described in the method part. Detection utilizing mono specific antibody which binds to N-
domain showed full length CEACAM1 whereas using antibodies binding to the A1-B domains 
or to the linker between B-A2 domains showed both full length and truncated CEACAM1. 
The detection of beta-actin served as loading control. These are representative data of three 
separate experiments. 
4.4.2 The deglycosylated 95 kDa CEACAM1 variant corresponds to the 
deglycosylated truncated CEACAM1 variant found in epithelial cells 
To investigate whether, the decreased molecular weight of full length CEACAM1 to 95 kDa 
represent a different glycosylated version of the truncated 72 kDa CEACAM1 variant found in 
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urine deglycosylation experiments were carried out. The truncated CEACAM1 in epithelial 
cells is approximately 72 kDa whereas in endothelial it is an N-domain less 95 kDa variant. In 
parallel, deglycosylation was performed using A549 cells as control. The results showed that 
both the 95 kDa CEACAM1 found in endothelial as well as the 72 kDa variant found in 
epithelial reduced to 40 kDa after deglycosylation (Figure 32). Thus, the results 
demonstrated that the 95 kDa CEACAM1 variant in endothelial cells has apparently a 
different glycosylation in comparison to that of epithelial cells because when deglycosylated it 
corresponds to the degylcosylated truncated CEACAM1 variant found in epithelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Characterization of non-deglycosylated and deglycosylated CEACAM1 
expressed in endothelial and epithelial cells.  
Deglycosylation assay was performed using PNGase F enzyme treatment on 
immunoprecipited CEACAM1. Subsequently, the samples were analyzed by Western blot 
and detected by a monoclonal anti-CEACAM1. The data shown are representative of three 
separate experiments. 
4.4.3 Truncated CEACAM1 due to protein turn-over processes in endothelial cells 
Having learnt from the previous results that truncated CEACAM1 in epithelial cells appeared 
due to long term culturing of confluent epithelial cells we repeated this approach using the 
AS-M.5 endothelial cell line. AS-M.5 cells were seeded in 25 mm2 culture flask, the cell 
lysates were collected when they reached confluent plus 4 weeks. Results showed very low 
expression of CEACAM1 at just confluent state (Figure 33). However, the expression was 
significantly increased in confluent plus four weeks samples. Detection using monoclonal 
antibody 18/20 showed faint and broad bands at 160 kDa representing the full length 
CEACAM1 in just confluent and confluent plus four weeks samples respectively (Figure 33 
left panel). Furthermore, detection by using C5-1X showed faint and broad bands at 160 kDa 
representing the full length CEACAM1 in just confluent and confluent plus four weeks 
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samples respectively (Figure 33 middle panel). In addition C5-1X showed a very weak band 
at 95 kDa in confluent plus four weeks sample. Interestingly, detection by using the 
monoclonal antibody 4D1/C2 showed faint and broad bands at 95 kDa in confluent and 
confluent plus four weeks samples, respectively (Figure 33 right panel). Note, that the 95 
kDa was not detected with an N-domain binding antibody confirming that truncated 
CEACAM1 in endothelial cells lacks N-domain. The results showed that truncated CEACAM1 
in endothelial cells appeared due to molecular protein turnover. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Up regulation of full length and truncated CEACAM1 in contacted-inhibited 
endothelial cells.  
AS-M.5 cells were cultured and there whole cell lysates collected after the cells growth 
stages as indicated above. Subsequently, samples were analyzed by Western blot and the 
determination of CEACAM1 was done by using three monoclonal anti-CEACAM1 antibodies. 
The detection of beta-actin served as loading control. The data shown are representative of 
three different experiments. 
4.4.4 Release of both full length and truncated CEACAM1 are released into the cell 
culture supernatant of long term cultured endothelial cells 
To determine whether, the increase of full length and truncated CEACAM1 in the endothelial 
cells corresponds with the secreted amount into the culture cell culture supernatant sandwich 
ELISA was performed (Figure 34A). As shown in figure 34 line 1 no CEACAM1 was detected 
in the just confluent samples. However, CEACAM1 was a significantly increased to 0.8 ± 0.1 
optical density (n=3) in the confluent plus four weeks sample. These results demonstrated 
that CEACAM1 is released into the cell culture supernatant when the cells were kept in 
contact inhibited state. 
To confirm this results immunoprecipitation of the samples was performed. As shown below 
no band was detected in the confluent samples. However, detection by using monoclonal 
antibody 4D1/C2 revealed a weak band at 160 kDa and additional broad band at 95 KDa in 
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confluent plus four weeks sample (Figure 34 B left panel). In addition, detection using 
monoclonal antibody C5-1X revealed faint bands at 160 kDa, 95 kDa and at 55 kDa in the 
same sample (Figure 34 B right panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Determination of soluble CEACAM1 released from contact inhibited 
endothelial cells.  
A) For quantification of CEACAM1 released in contact-inhibited endothelial cells, samples 
were analyzed by sandwich ELISA as described in the method section. As positive control 
HeLa-CEACAM1-4L cell lysates was included. The values ± SD were determined from 
triplicates. B) For detection of CEACAM1 released into cell culture supernatant 
immunobloting analysis was performed as described in the method section. The presented 
data are representative of three separate experiments. 
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4.5 Characterization of full length CEACAM1 in urine 
4.5.1 Release of full length CEACAM1 from the cells in membrane-bound vesicles 
We found that only truncated CEACAM1 is present in urine whereas epithelial and 
endothelial cells released both full length as well as truncated CEACAM1. To elucidate this 
discrepancy we analyzed the pellets obtained from urine after centrifugation. The urine 
samples from patients suffering from bladder cancer were subjected to centrifugation as 
described in the method part. The pellets obtained were then analysed by Western blot 
analysis. The results showed broad bands at 120 kDa indicating high amount of full legth 
CEACAM1 in the pellets (Figure 35). However, no truncated CEACAM1 was detected. The 
results shows that the full length CEACAM1 is usually released as membrane-bound 
whereas truncated CEACAM1 are soluble. 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Detection of full length as well as truncated CEACAM1 found in urine 
pellets.  
The urine samples were subjected to centrifugation as described in the method section. 
Subsequently, the pellets ware collected and analyzed by Western blot as described in the 
method section. The blot was developed using monospecific Anti-CEACAM1 antibody. 
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5. Discussion 
Although it was published that no CEACAM1 is released into human urine (Draberova et al., 
2000; Svenberg, 1976b), soluble forms have recently been reported to be present in urine of 
healthy donors. Interestingly, its urine concentration was significantly higher in patients 
suffering from bladder cancer (Tilki et al., 2009). However, the soluble CEACAM1 found in 
urine was not yet sufficiently characterized. Therefore, this study focused on the protein 
biochemical characterization of CEACAM1 found in urine, particularly on mechanisms 
leading to generation of this CEACAM1 form and the determination of its putative cellular 
origin. Furthermore, we wanted to learn more about the cause leading to the CEACAM1 
secretion and the detailed mechanism behind these processes. 
5.1 Soluble CEACAM1 is present in human urine 
Normally CEACAM1 is expressed on the cell surface of various cell types. It has been shown 
that it is expressed on epithelial cells, and angiogenicly activated endothelial cells (Horst and 
Wagener, 2004; Prall et al., 1996; Ergun et al., 2000b; Kilic et al., 2005). It is also expressed 
on various hematopoietic cell types such as granulocytes, B cells, T cells, natural killer (NK) 
cells and dendritic cells (Kammerer et al., 1998; Khan et al., 1993; Moller et al., 1996b; 
Singer et al., 2002; Watt et al., 1991). Beside the transmembrane-bound form soluble 
CEACAM1 variants has been reported. Presence of soluble CEACAM1 has been reported in 
the serum of healthy donors (Svenberg et al., 1981). Furthermore, increased serum levels of 
soluble CEACAM1 were observed in patients with liver diseases such as obstructive 
jaundice, hepatitis A or B, and cytomegalovirus-induced hepatitis (Draberova et al., 2000; 
Svenberg et al., 1979). In addition, soluble CEACAM1 has been found in human bile 
(Svenberg, 1976b). In contrast to these literature reporting the existence of soluble 
CEACAM1 it was reported that soluble CEACAM1 was not detectable in urine (Draberova et 
al., 2000). On contrary, our group recently found CEACAM1 in urine of healthy donors and at 
significantly higher concentration in urine samples of patients with bladder carcinoma (Tilki et 
al., 2009). In addition, Tilki et al., 2009 observed CEACAM1 bands with 120 kDa and another 
with approximately 72 kDa. However, the origin of soluble CEACAM1 was not investigated. 
To further investigate this CEACAM1 form we first determined the concentration of 
CEACAM1 in urine of healthy donors in comparison with the well characterized concentration 
of CEA. CEA in urine was previously reported to be in the range of 7-11 ng/ml (Guinan et al., 
1974). Our results showed concentration of 7 ng/ml ± 5 ng/ml (n=12) for CEA (Figure 11 left 
panel). Surprisingly, the concentration of CEACAM1 was significantly higher having 200 
ng/ml ± 110 ng/ml (n=16) (Figure 11 right panel). However, CEACAM1 showed a very large 
standard deviation with the highest been ten fold higher than the smallest. This may be due 
to individual differences arising from diet, and also it may be due to differences in the time 
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urine was collected (24-hours or morning collection). To confirm the presence of CEACAM1 
in urine immunobloting analysis was performed. Our results revealed a significant band with 
molecular weight of 72 kDa band (Figure 12 line 4) which confirms the findings published in a 
recent study (Tilki et al., 2009). On the contrary, we did not detect the 120 kDa CEACAM1 
form as shown by Tilki et al. 
Next, we analyzed if CEACAM1 found in urine is soluble or membrane-bound. This was 
performed using ultracentrifugation and Triton X-114 phase separation assays. Our results 
showed that main part of CEACAM1 was detected in the hydrophilic fraction and minor part 
in the hydrophobic fraction (Figure 13A and B). Therefore, approximately 90% of the 
CEACAM1 found in urine represent soluble and not membrane-anchored. 
5.1.1 72 kDa CEACAM1 variant found in urine does not represent a deglycosyleted 
variant of full length CEACAM1 
Depending on the cell type the molecular weight of CEACAM1 can be 120-160 kDa due to 
differences in glycosylation (Kannicht et al., 1999; Lucka et al., 2005). For example, 
CEACAM1 on PMNs cells have a molecular weight of 160 kDa (Lucka et al., 2005) whereas 
epithelial and endothelial cells have 120 kDa and 140 kDa respectively (Bamberger et al., 
1998; Prall et al., 1996). However, due to the protein marker we used in this study 
sometimes the molecular weight was higher. Therefore, in this study we decided to use 120 
kDa to represent full length CEACAM1. 
To determine whether the reduction from 120 kDa to 72 kDa may occur due to glycosylation 
differences, CEACAM1 in urine was subjected to deglycosylation using PNGase enzymes. 
Deglycosylation of the 72 KDa CEACAM1 precipitated from urine resulted in a 40 kDa band 
(Figure 14A right panel). Furthermore, deglycosylation of the human CEACAM1-Fc reduced 
its molecular weight from 120 kDa to 75 kDa (Figure 14A left panel). This clearly 
demonstrated that the 72 kDa CEACAM1 detected in urine is glycosylated and does not 
represents a deglycosylated variant of full length CEACAM1. Calculating from our results the 
reduction of full length CEACAM1 from 120 kDa to 75 kDa showed that 62.5% consists of 
sugar. Whereas truncated CEACAM1 consist of 55.5% sugar. These corresponded with what 
is known from the literature that more than half of the molecular weight of CEACAM1 
consists of carbohydrates (Lucka et al., 2005). 
Beside proteins been secreted from the body via urine they can also be secreted through 
feces. This led us to analyse CEACAM1 in comparison with CEA in feces. Immunobloting 
analyses on feces samples revealed a strong band with molecular weight of 40 kDa (Figure 
14B right panel). It is likely that CEACAM1 detected in feces is deglycosylated for it 
corresponds with the deglycosylated CEACAM1 in urine. However, CEACAM5 in feces 
revealed most prominent band at 180 kDa (Figure 14B left panel). This prominent band 
corresponded with previous report (Kuroki et al., 1981). It is likely that the deglycosylation of 
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CEACAM1 in feces is carried out by digestive enzymes or by microorganisms in the colon. 
Taken together our results clearly demonstrated that the reduction of molecular weight from 
120 kDa to 72 kDa is not due to differences in glycosylation of CEACAM1. 
5.1.2 Soluble CEACAM1 found in urine lacks the N-terminal domain and part of A2 
domain 
Next, we analyzed if the reduced molecular weight appears due to different number of 
domains as observed in CEACAM1 isoforms. For example, CEACAM1-4 isoforms have the 
A2 domain which is missing in the CEACAM1-3 isoforms. We established a different 
sandwich ELISA to distinguish between the N-terminal domain, A1B1, A2, and cytoplasmic 
domain respectively. Our results revealed that the 72 kDa CEACAM1 variant found in urine 
does not contain the N-domain, part of the A2 domain and cytoplasmic tail (Figure 15A). 
Therefore, CEACAM1 in urine represent a truncated variant consisting of the A1, B domains 
and a part of the A2 domain. Because all eleven expressed isoforms of CEACAM1 contain 
the N-domain, the truncated CEACAM1 variant can not be one of the splice variants. 
Therefore, we present here for the first time a novel truncated variant of CEACAM1.   
These clearly demonstrate that Draberova et al., were not able to detect CEACAM1 in urine 
because they utilized an antibody that binds to the N-domain which according to our results it 
is missing. On other hand we detected it because we used antibody that binds at the linker 
between B and A2 domains.  
We further performed epitope mapping of CEACAM1 found in hydrophilic fraction of urine 
after ultracentrifugation. Our results confirmed that the CEACAM1 in the hydrophilic fraction 
does not contain the N-domain, part of the A2 domain and cytoplasmic tail (Figure 15B). 
Taken together our results clearly demonstrate that CEACAM1 found in urine is a truncated 
variant and this variant might originate from hematopoetic, epithelial and endothelial cells. 
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5.2 Granulocytes are not likely the source of truncated CEACAM1 
Human polymorphonuclear leukocytes (PMNs; neutrophils or granulocytes) are critical for 
innate host defense and comprise the single greatest cellular component of the immune 
system. Approximately 60% of all human leukocytes are granulocytes (Bainton et al., 1971). 
PMNs cells have the broadest CEACAM1 expression. This led us to investigate whether 
PMNs cells would be the likely source of truncated CEACAM1. Western blot analysis by 
applying two monoclonal antibodies 18/20 (binds the N-domain) and 4D1/C2 (binds the linker 
between B and A2 domains) revealed that PMNs cells express only the full length but not the 
truncated CEACAM1 (Figure 16).  
Having shown that PMN cells do not endogenously express truncated CEACAM1 we thought 
that it may be generated when they under spontaneous apoptosis. It is important that 
neutrophils undergo constitutive (spontaneous) apoptosis as a mechanism to facilitate 
normal cell turnover and immune system homeostasis (Haslett et al., 1991). Normally, 
granulocytes are short-lived cells with a half-life of only 6-20 hours in the circulation, after 
which they undergo apoptosis. Previous studies reported that healthy donors produce and 
destroy 180 x 107 granulocytes per day (Haslett et al., 1991; ATHENS et al., 1961). 
Immunoblot analysis of the cell lysates after spontaneous apoptosis revealed full length 
CEACAM1 but not truncated CEACAM1 (Figure 17A lines 1 and 2). Furthermore, analysis of 
the supernatant obtained indicated that spontaneous apoptosis did not lead to secretion of 
truncated CEACAM1 but rather a small fraction of full length CEACAM1 (Figure 17A line 3).  
These results were expanded using a Fas ligand (FasL) which is a potent inducer of 
apoptosis in granulocytes (Simon, 2003). The interaction of FasL with its receptor results in 
the activation of a defined downstream caspase cascade, which amplifies the apoptotic 
process (Sharma et al., 2000). Our results revealed that truncated CEACAM1 was not 
detected in the cell lysates even after induced apoptosis (Figure 17B line 1 and 2). 
Furthermore, truncated CEACAM1 was not detected in the supernatant (Figure 17B line 3). 
Therefore, we conclude that truncated CEACAM1 is not expressed or secreted from 
granulocytes due to apoptosis processes. However, our findings seem to be in contrast to 
previous report that apoptosis on epithelial cells leads to cleavage of CEACAM1 (Nittka et 
al., 2008). These different results may be based on the fact that we used granulocytes where 
as Nittka et al. utilized epithelial cell lines. Therefore, suggesting that the role of CEACAM1 
during apoptosis processes depended on the cells type.  
It is commonly accepted that PMNs cells which are recruited to the site of infection or 
senescent PMN cells, eventually succumb to apoptosis and are swiftly ingested by 
macrophages (Savill et al., 1989). The clearance of PMNs cells by macrophages is a crucial 
process in events such as homeostasis, wound healing and tissue regeneration (Hart et al., 
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2008). Since PMN are short-lived cells their recognition and clearance must be extremely 
efficient. Apoptotic PMN cells that would not be removed by macrophages undergo necrosis 
leading to the release of their cytotoxic granular contents, and thus damaging the 
surrounding tissues (Haslett et al., 1994). Clearance of this apoptotic cells requires highly 
specific signals exposed on the surface (Lauber et al., 2004). In comparison to healthy cells, 
apoptotic cells contain altered proteins, lipids, and carbohydrates on their surface (Hart et al., 
2008). The best characterized of such molecule is the phospolipid phoshatidlylserine (PS) 
which relocates from the inner to the outer surface of the plasma membrane (Fadok et al., 
1992; Martin et al., 1995). This facilitates the recognition and ingestion of apoptotic PMNs 
cells.  
To mimic these physiological processes, PMNs cells and macrophages were co-cultured to 
determine whether truncated CEACAM1 do not appear due to these processes. 
Immunobloting analysis of the cell lysates after co-culture revealed that truncated CEACAM1 
appears not due to ingestion of PMN by macrophages (Figure 18 lines 1, 2, 4, 5, 7, and 8). In 
addition, no truncated CEACAM1 was detected in the cell culture supernatant (Figure 18 
lines 3, 6 and 9). These results clearly demonstrate that truncated CEACAM1 found in urine 
is probably not produced or secreted from ingestion of apoptotic PMNs cells by 
macrophages. 
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5.3 Epithelial cells are the likely source of truncated CEACAM1 
Epithelial cells are another type of cells that express significant amount of CEACAM1. This 
led us to investigate if epithelial cells are likely the source of truncated CEACAM1. 
Immunoprecipitation of CEACAM1 was performed on different epithelial cells (A549, T102/3, 
HT29, and HeLa-CEACAM1) using a monospecific antibody 4D1/C2. Subsequently, Western 
blot analysis using monoclonal antibody 18/20 revealed bands with molecular weight of 120 
kDa which corresponds to full length CEACAM1 but no truncated CEACAM1 (Figure 19A). 
However, detection by using the monoclonal antibody 4D1/C2 revealed bands with molecular 
weight of 120 kDa and 72 kDa (Figure 19 B). These results demonstrated for the first time 
that epithelial cells are likely the source of truncated CEACAM1. Furthermore, our results 
clearly demonstrated that truncated CEACAM1 was found in both endogenously and 
transfected CEACAM1 expressing epithelial cells. Therefore, we concluded that epithelial 
cells are likely source of truncated CEACAM1 variant. However, it was important to analyze if 
this reduction of molecular weight from 120 kDa to 72 kDa was due to different glycosylation.  
5.3.1 72 kDa CEACAM1 variant found in epithelial cells does not represent a 
deglycosylated variant of full length CEACAM1 
Deglycosylation assay was performed to determine whether the reduction of molecular 
weight from 120 kDa to 72 kDa was due to differences in glycosylation of CEACAM1. First of 
all CEACAM1 in epithelial cells was precipitated using monoclonal antibody B3 (binds A1B-
domains) then subjected to deglycosylation. Subsequently, Western blot analysis using 
monoclonal antibody 4D1/C2 revealed that deglycosylation of the full length CEACAM1 
reduced its molecular weight from 120 kDa to 75 kDa whereas the 72 kDa truncated 
CEACAM1 variant reduced to 40 kDa (Figure 20). This result clearly demonstrates that the 
72 kDa CEACAM1 variant does not represent a deglycosylated variant of full length 
CEACAM1. In addition, our results on the reduction of full length CEACAM1 from 120 KDa to 
approximately 75 kDa after deglycosylation are in accordance with previous reports (Nittka et 
al., 2008; Comegys et al., 2004). Furthermore, deglycosylated CEACAM1 bands were 
detected as weak bands suggesting the importance of sugar in antibody binding and once 
the sugars are removed the antigen-antibody interaction was weakend. 
5.3.2 CEACAM1 found in epithelial cells also lacks N-domain 
Next we analyzed whether the 72 kDa CEACAM1 variant expressed in epithelial cells lacks 
the N-domain as in case of CEACAM1 found in urine. This was addressed by epitope 
mapping using immunoblot analysis. Immunoprecipitation was performed using monoclonal 
antibodies B3 and 4D1/C2. Subsequently, Western blot using monoclonal antibody 18/20 
revealed bands with molecular weight of 120 kDa (Figure 21 left panel). Thus, indicating that 
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the 72 kDa CEACAM1 variant does not have N-domain. However, detection by using the 
monoclonal antibody 4D1/C2 revealed two bans with molecular weight of 120 kDa and 72 
kDa (Figure 21 right panel). Taken together our results clearly demonstrated that the 72 kDa 
CEACAM1 found in epithelial cells lacks the N-domain. Therefore, similar to epitope mapping 
of CEACAM1 found in urine it clearly shows that the 72 kDa CEACAM1 is a truncated variant 
of CEACAM1 which do not have the N-domain. 
5.3.3 Truncated CEACAM1 appears not due apoptosis process 
It was recently reported that induction of apoptosis on epithelial cells leads to cleavage of 
CEACAM1 (Nittka et al., 2008). This led us to determine if truncated CEACAM1 appears due 
to apoptosis. We therefore performed a detailed analysis of apoptosis using apoptotic 
inducing agents such as actinomycin, campthecin, cycloheximide, dexamethasone and 
etoposide. Because all apoptotic inducing agents had almost similar results in this study we 
only use the results of actinomycin. Flow cytometric analysis of Annexin V-FITC/Propidium 
Iodide (PI) stainings showed that actinomycin led to a significant cell death showing 
approximately 5% cell survival after 24 hours in A549 cells (Figure 22A and B). Western blot 
analysis revealed full length but not truncated CEACAM1 variant (Figure 22 C). In addition, in 
our investigation we did not detect a 14 kDa on fragment of N-domain as previously report by 
Nittka et al. These results clearly demonstrated that in our experiments truncated CEACAM1 
does not appear due to apoptosis.  
5.3.4 Truncated CEACAM1 variant appears not due to down regulation of full length 
CEACAM1 when contact-inhibited resting epithelial cells enter the proliferation 
It was recently, reported that A549 (human alveolar type 11) epithelial cells that had reached 
confluency did not express CEACAM1 but increased as cell entered the post-confluent 
growth arrest state reaching to high expression at day seven (Singer et al., 2010). In addition 
Singer et al., showed a significant down regulation of cell surface CEACAM1 when contact 
inhibited cells are entering the proliferation phase. Thus, it was tempting to speculate that 
this down regulation leads to the truncated CEACAM1 variant. Surprisingly, our results 
revealed a significant down regulation of truncated CEACAM1 with complete disappearance 
after three days when contact inhibited cells began to proliferate (Figure 23A). We show that 
although the full length CEACAM1 expression disappeared no increased amount of 
truncated CEACAM1 was detectable. In addition our results revealed for the first time a down 
regulation of truncated CEACAM1. Further we investigated whether this downregulation of 
full length and truncated CEACAM1 leads to an increase in the supernatant. Sandwich 
ELISA analysis of the supernatants showed very small amount of CEACAM1 released in 
post-confluent cells (day 0) whereas nothing was detected in proliferating cells (Figure 23B). 
In addition, Western blot analysis revealed no full length as well as truncated CEACAM1 in 
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the cell culture supernatant (data not shown). Therefore, we concluded that truncated 
CEACAM1 does not appear or secreted from epithelial cells due to down regulation of full 
length CEACAM1 expression when contact-inhibited cells entered the proliferative stage. 
The down regulation of full length and truncated CEACAM1 implies that proliferating cells 
needs a lot of energy. Thus, they do not release full length or truncated CEACAM1 but rather 
every thing is reused. Therefore, this is a type of CEACAM1 turnover process whereby the 
cell reuses every from CEACAM1 which includes amino acids and sugars.  
We next quantified CEACAM1 expression in different cell growth phases of epithelial cells, 
using quantitative flow cytometry approach. The cells were stained with monoclonal antibody 
18/20 and the level of CEACAM1 expression was determined in reference to calibration 
beads conjugated with a known amount of antigen for secondary antigen. In log phase of 
HT29 and T102/3 cells a significant expression of approximately 8,000 ± 1500 (n=4) 
molecules per cell was observed where as in case of A549 cells no CEACAM1 expression 
on the surface of was detected. However, a signification up-regulation with approximately 
18,000 ± 4000 (n=4) molecules per cell was observed when all cell types were kept at 
confluency (Figure 24).  
5.3.5 Truncated CEACAM1 appears in significantly amount in contact inhibited 
resting epithelial cells 
Contact-inhibition is the process of arresting cell growth when cells come close to each other. 
As a result normal cells stop proliferation when they form a monolayer in a culture dish. 
Cancer cells mostly do not arrest their growth when they fill a culture dish but continue to 
proliferate, piling up on top of each other and forming multilayered foci. The loss of contact-
inhibition is a hallmark of malignant cancer cells, leading to higher proliferation rate 
(Hanahan and Weinberg, 2000). Recently, it was reported that A549 cells that had reached 
confluence did not express CEACAM1 but the expression increased as cell entered the post-
confluent contact inhibited growth stage (Singer et al., 2010). This led us to investigate 
whether the increase of full length CEACAM1 during post-confluent phase would lead to 
appearance of truncated CEACAM1. We therefore analyzed different epithelial cell lysates 
(A549, T102/3, and HT29) when cells were confluent, confluent plus one week, confluent 
plus two weeks, and confluent plus three weeks. Western blot analysis of A549 cells (Figure 
25A right panel) using monoclonal antibody 18/20 showed no truncated CEACAM1 any of 
the samples. Thus, confirming that truncated CEACAM1 does not have N-domain. However, 
using monoclonal antibodies C5-1X and 4D1/C2 weak bands of truncated CEACAM1 were 
observed in the confluent samples (Figure 25A lines 2 and 3). Interestingly, it was observed 
that the truncated CEACAM1 continuously increased as the cell were kept in contact 
inhibition growth phase (Figure 25A middle and left panels). Western blot analysis of T102/3 
(Figure 25B) and HT29 (Figure 25C) revealed the same increase of full length and truncated 
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CEACAM1 in contact inhibited cells. Furthermore, detection by using the three monoclonal 
antibodies revealed a continuous increase of full length CEACAM1 in all three epithelial cells 
(Figure 25A, B and C). This finding was expanded by quantitative flow cytometric analysis of 
cell surface CEACAM1. The CEACAM1 expression was analyzed as cells were just 
confluent, confluent plus one week, confluent plus two weeks, and confluent plus three 
weeks (Figure 26). The results showed low expression of CEACAM1 in just confluent cells. 
However, the expression progressively increased attaining approximately 25,000 ± 2,200 
(n=3), 41,000 ± 5,030 (n=3), and 22,000 ± 1,850 (n=3) molecules per cell in A549, T102/3 
and HT29 cells, respectively. 
Taken together, our results revealed for the first time that truncated appeared in contact-
inhibited cells and significantly increased as were cell kept longer in contact inhibited growth 
state.  
5.3.6 Contact inhibited resting epithelial cells, but not proliferating cells release 
truncated CEACAM1 
Next, we analyzed using sandwich ELISA the cell culture supernatants obtained from 
epithelial cells kept in contact inhibited state. Our results revealed a continuous increases of 
released CEACAM1 (Figure 27A). Using immunobloting analysis no truncated CEACAM1 
was observed in confluent samples (Figure 27B lines 1, 4, 7, 10, 13, and 16). This clearly 
demonstrates that truncated CEACAM1 is not released during cell proliferation. However, 
significant amount of truncated CEACAM1 was observed in samples of cells with one week 
and two weeks after conflueny (Figure 27B). These clearly demonstrate that truncated 
CEACAM1 variant is released from contact inhibited resting epithelial cells. In addition it was 
significantly increased as contact inhibited cells well kept longer. Furthermore, our results 
revealed an increasing amount full length CEACAM1 (Figure 27B).Taken together our results 
demonstrated that full length as well as truncated CEACAM1 is significantly released from 
contacted inhibited cells. In comparison to our earlier results obtained from urine analyses 
these findings show not only the truncated CEACAM1 is released. To elucidate this 
discrepancy, additional studies were done using urine as explained in section (4.5). 
However, the functions of transmembrane-bound and soluble full length CEACAM1 are well 
known. The cytoplasmic domain of CEACAM1 contains two phosphorylable tyrosine residues 
in the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are important in the 
regulation of signal transduction (Obrink, 1997a). After tyrosine phosphorylation, CEACAM1–
4L can bind and activate src-family tyrosine kinases (Brummer et al., 1995; Skubitz et al., 
1995) as well as the SH2-domain-containing protein tyrosine phosphatases SHP1 and SHP2 
(Beauchemin et al., 1997). In addition, an increased intracellular calcium concentration leads 
to binding of calmodulin to the cytoplasmic domains of both the L and the S isoforms, which 
influences CEACAM1 dimerization (Edlund et al., 1996a). Interactions of CEACAM1 with the 
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actin filament system also have been observed (Da Silva-Azevedo and Reutter, 1999; Hunter 
et al., 1994). The cytoplasmic domain of CEACAM1-L confers on FcуR11B the capacity to 
inhibit B-cell antigen receptors (BCR) (Chen et al., 2001). Furthermore, it has been reported 
that tumor suppressive effect of CEACAM1 depends on the presence of its cytoplasmic 
domain (Izzi et al., 1999; Turbide et al., 1997). Cytoplasmic domain of CEACAM1 is also 
essential during formation of insulin-insulin receptor (IR) complex (Choice et al., 1998; Najjar 
et al., 1998). Therefore lack of cytoplasmic domain by the truncated CEACAM1 means it can 
not to be involved in the above mentioned signal transductions involving cytoplamic domain. 
 
It is well established that CEACAM1 mediates intercellular interactions using its N-domain 
(Watt et al., 2001; Markel et al., 2004a; Stern et al., 2005; Klaile et al., 2009a). In addition, it 
was shown that the trans-homophilic CEACAM1 binding induces cis-dimerization by an 
allosteric mechanism transmitted via the N-domain (Muller et al., 2009a). Furthermore, trans-
binding between the N-domains changes CEACAM1 interactions with microcluster (Klaile et 
al., 2009a). Studies have shown that Opa proteins expressed by Neisseria gonorrhoeae and 
Neisseria meningitides, bind specifically to the N-domain of CEACAM1 (Gray-Owen et al., 
1997; Bos et al., 1999). The binding UspA1 proteins expressed by Moraxella catarrhalis on 
CEACAM1 also occurs through the N-domain (Hill and Virji, 2003). Other studies have 
shown that of Escherichia coli and salmonella strains expressing Dr family of adhesins bind 
CEACAM1 on the N-domain (Korotkova et al., 2006). In addition, ligation of CEACAM1 with 
monoclonal antibody addressing N-domain stimulates β2-integrin-dependent neutral 
aggregation (Kuijpers et al., 1993) and adherence of neutrophils to HUVECs (human 
umbilical vein endothelial cells) (Kuijpers et al., 1992). Furthermore, synthetic peptides 
containing sequences of the N-domain of CEACAM1 can initiate signal transduction in 
neutrophils (Skubitz et al., 2001; Skubitz and Skubitz, 2010). It has been shown that N-
domain is crucial for enhancing insulin endocytosis (Soni et al., 1999). Our results have 
clearly demonstrated that, truncated CEACAM1 lacks the N-domain which is essential in 
many CEACAM1 functions. Therefore, lack of N-domain by the truncated CEACAM1 means 
it can not be involved in the any CEACAM1 function involving N-domain.  
Several functions of soluble CEACAM1 have been reported. Recently, soluble full length 
CEACAM1 was shown to exhibit angiogenic properties in vitro and in vivo (Ergun et al., 
2000b). It was demonstrated that CEACAM1 mediated inhibition of NK cell killing activity is 
specifically abrogated in the presence of soluble full length CEACAM1 (Markel et al., 2004b). 
In addition CEACAM1 can also act a co-inhibitor of T cells receptor (TCR) responses when 
bound with soluble full length CEACAM1-Fc (Chen et al., 2004). However, soluble truncated 
CEACAM1 has never been reported. We suggest that lack of N-terminal and cytoplamic 
domains by the soluble truncated CEACAM1 imply it can not involved in any CEACAM1 
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function. Furthermore, it can not be used a ligand due to lack of N-domain for example 
CEACAM1-∆N-Fc (without N-domain) constructs are mostly used as a negative control. 
Therefore, we suggest that this is a type of CEACAM1 turnover process in epithelial cells 
when they do not need all CEACAM1 thus removes the cytoplasmic and the N-domains 
making it not dangerous. 
5.3.7 Truncated CEACAM1 is generated by internalization mechanism of full length 
CEACAM1 as molecular turnover process 
Some studies have shown that transmembrane proteins can not sufficiently be degraded by 
proteinases as long as they are membrane bound. For example the urokinase receptor 
uPAR (Montuori et al., 2005) and CD44 (Lammich et al., 2002) are cleaved within the cell 
membrane. Then, these fragments are internalized and moved to the lysosomes for 
degradation. In confluent contact-inhibited cells the truncated CEACAM1 accumulated in the 
cell as well as in the supernatant. Biotinylation studies should help to reveal if truncated 
CEACAM1 comes from the surface. A549 cells were incubated with sulfo-NHS-LS biotin one 
ice for one hour. Then immediately the biotinylated proteins were isolated by affinity 
purification using streptavidin agarose beads. Subsequently Western blot analysis revealed 
that only full length CEACAM1 was biotinylated but not truncated CEACAM1 (Figure 28B). 
Therefore, confirming that truncated CEACAM1 is not localized on the surface due to lack of 
the cytoplasmic domain. Next we analyzed the generation of truncated CEACAM1 by 
culturing biotinylated A549 cells at 37°C to allow the biotinylated molecules to be internalized. 
Western blot analysis of cell lysates after culturing for 15, 30, 45, and 60 minutes revealed 
only full length CEACAM but not truncated CEACAM1 (Figure 29A). Furthermore, increase of 
culturing time to one hour, three hours, five hours and 8 hours respectively demonstrated 
similar results (Figure 29B). The increase of culturing time to 24 hours demonstrated 
significant band at 120 kDa and a week band at 72 kDa. However, as the cells were cultured 
longer these bands became less and in day 4 no truncated CEACAM1 was visible (Figure 
29C). To determine whether the disappearance of both biotinylated full length and truncated 
CEACAM1 could result to secretion into the cell culture supernatant, affinity purification using 
streptavidin agarose beads was performed. Interestingly, no biotinylated CEACAM1 was 
observed in the supernatant (data not shown). This may suggest that once full length 
CEACAM1 was internalized, truncated CEACAM1 was generated, and immediately protease 
enzymes within the cells cleave the biotin out, resulting into not biotinylated CEACAM1 in the 
cell culture supernatant. Additional studies are needed to investigate the pathway involved in 
the internalization processes. 
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5.3.8 CEACAM1 is regulated at translational but not transcriptional level in epithelial 
cell during contact-inhibited growth phase 
Based on the a fore mentioned findings we next we investigated if CEACAM1 mRNA varied 
during contact-inhibited grow phase and if it is similar to the continuous increase as observed 
on full length and truncated CEACAM1. Our results demonstrated that the level of CEACAM1 
mRNA remained constant in contact-inhibited epithelial cells (Figure 30). Furthermore no 
changes on the mRNA level were observed even after three weeks when cells were kept in 
the contact inhibited state. This suggests that the significant increase of full length and 
truncated CEACAM1 in contact-inhibited cells may be due to increased translation of protein 
but not due to transcription as mRNA levels remained steady state. However, truncated 
CEACAM1 may come from new synthesis. This happens when the cells constitutively 
produce CEACAM1 but the cell does not need all CEACAM1 produced, thus it degraded it to 
truncated CEACAM1 before reaching the cell surface. These may be the reason why we 
were not able to observe truncated variants of CEACAM1 after biotinylation. 
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5.4 Endothelial cells represent an additional source of truncated CEACAM1 
Beside leukocytes and epithelial cells CEACAM1 is also expressed on angiogenicly activated 
vascular and lymphatic endothelial cells (Ergun et al., 2000b; Kilic et al., 2005; Kilic et al., 
2007). Endothelial cells represent a special form of epithelial cells thus it was tempting to 
speculate that also these cells might express truncated CEACAM1. To this aim a cortex 
endothelial cell line (AS-M.5) was used in our analysis. Our results revealed that full length 
CEACAM1 from epithelial cells was lower than that detected in endothelial cells (Figure 31). 
This results are in accordance with several reports indicating that molecular weight varies 
due to the level of CEACAM1 glycosylation depending on the cell type (Kannicht et al., 1999; 
Lucka et al., 2005). Interestingly it was noted that immunobloting analyses using the 
monoclonal antibody 4D1/C2 (bind to the linker between B and A2 domains) showed a 72 
kDa in epithelial cells whereas in endothelial cells it was significantly higher with 95 kDa 
(Figure 31 right panel). Detection by using C5-1X revealed full length CEACAM1 in epithelial 
as well as in endothelial cells. In addition, a weak band of truncated CEACAM1 was detected 
in epithelial cell (Figure 31 middle panel). Further investigations were done to determine 
whether this 95 kDa variant mimic the N-domain truncated CEACAM1 detected in epithelial 
cells. Detection by using monoclonal antibody 18/20 did not detect the 95 kDa variant in 
endothelial cells (Figure 31 left panel). Therefore, indicating that the 95 kDa variant lacks the 
N-domain. However, epitope mapping using sandwich ELISA was controversial because it 
revealed this truncated CEACAM1 have N-domain. To elucidate this discrepancy, additional 
studies were done using deglycosylation assay. Subsequently, Western blot analysis using 
the monoclonal antibody 4D1/C2 revealed that deglycosylation of the truncated CEACAM1 
reduced its molecular weight from 95 KDa to 40 kDa (Figure 32 right panel). This result 
clearly demonstrates that the 95 kDa CEACAM1 variant is glycosylated and represents not a 
deglycosylated variant of full length CEACAM1 in endothelial cells. This finding corresponds 
to the deglycosylated truncated CEACAM1 in epithelial cells (Figure 32 left panel). Although 
there was no 95 kDa CEACAM1 form detected in urine we suggest that the 95 kDa 
CEACAM1 variant released by endothelial cells is deglycosylated on the way to excretion to 
form a 72 kDa CEACAM1 form. Therefore, endothelial cells are probably an additional 
source of the 72 kDa truncated CEACAM1 variant found in urine. 
5.4.1 Truncated CEACAM1 appears due to turnover processes in contact-inhibited 
endothelial cells 
Next, we investigated whether this 95 kDa variant found in endothelial cells is upregulated 
similar to truncated CEACAM1 detected in epithelial cells. Western blot analysis using 
monoclonal antibodies 18/20 and C5-1X revealed a significant upregulation of full length 
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CEACAM1 when the cells were kept in contact inhibited state (Figure 33 left and Middle 
panel). Furthermore, Western blot analysis using monoclonal antibody 4D1/C2 revealed that 
the 95 kDa variant appeared in contact-inhibited (Figure 33 right panel). In addition, the 95 
kDa CEACAM1 variant was significantly upregulated when the cells were kept in contact 
inhibited state. Further, we analyzed using sandwich ELSA the presence of CEACAM1 in the 
cell culture supernatants obtained from contact-inhibited endothelial cells. Our results 
revealed a continuous increases of released CEACAM1 (Figure 34A). To confirm these 
results immunoprecipitation was performed. Western blot analysis using 4D1/C2 revealed a 
weak band at 120 kDa and a broad band at 95 kDa in confluent plus four weeks samples 
(Figure 34 B left panel). However, detection using by the monoclonal antibody C5-1X 
revealed a weak band at 120 kDa, 95 kDa and a smear at 55 kDa. As shown in figure 34 no 
band was detected in the confluent samples. It was shown that CEACAM1 is expressed in 
endothelial cells of newly formed small vessels of angiogenic tissues such as in tumors, 
regeneration of endometrium, and placenta and wound healing, but not in quiescent blood 
vessels of normal human tissues (Ergun et al., 2000b). They also showed that once the 
blood vessels are stabilized CEACAM1 was not detected or weakly detected. Taken 
together, our results suggest a CEACAM1 turnover process in endothelial cells whereby the 
endothelial CEACAM1 expression is downregulated in form of truncated CEACAM1 once 
blood vessels switch from an angiogenic to a quiescent phenotype. However further studies 
are needed for the characterization of the 95 kDa variant found in endothelial cells. 
5 Discussion 
108 
5.5 Full length CEACAM1 is released from the cells in membrane-bound vesicles 
It is well known that normal and malignant cells release part of their cell surface membrane 
to form circular membrane fragments called microvesicles (MV). Shedding of membrane-
derived MV is physiological phenomenon that accompanies cell activation and growth 
(Beaudoin and Grondin, 1991; Tesse et al., 2006; Hugel et al., 2005). Interestingly, rapidly 
growing cell lines tend to secrete more MV than slowly growing cells. Generally, the number 
of MV shed from cells can be increased by factors such as cell activation, hypoxia, 
irradiation, oxidative injury, and shear stress (Hugel et al., 2005; Horstman et al., 2004; Barry 
and FitzGerald, 1999). MV contain numerals proteins and lipids similar to those present in 
the cell plasma (Hunter et al., 2008). Recently carcinoembryonic antigen (CEA), was 
observed on various MV shed from human breast carcinoma cells (Dolo et al., 1995).  
We found that only truncated CEACAM1 is present in urine whereas epithelial and 
endothelial released both full length as well as truncated CEACAM1. To elucidate this 
discrepancy we analyzed the pellets obtained from urine after centrifugation. Immunobloting 
analysis revealed bands with 120 kDa which corresponds to the full length CEACAM1 but not 
to the truncated CEACAM1 variant (Figure 35). These data clearly demonstrates that full 
length CEACAM1 are released as membrane bound whereas truncated CEACAM1 are 
soluble because they were not detected in the urine pellet. This may imply that full length 
CEACAM1 found in the cell culture supernatants are also membrane bound and may have 
originated due to cell culture medium turning to acidic pH during cell culturing. However, 
further analyses on microvesicle containing CEACAM1 released by tumor cells are needed, 
furthermore, their biological functions. 
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5.6 Characterization of antibodies used in this study 
The monoclonal antibodies used in this study were specifically binding to the various 
domains as follows: 18/20, R+D (N-domain), B3 (A1 domain), C5-1X (B domain) 4D1/C2 (the 
linker between B-A2 domains), 8G5 (A2 domain) and anti-CEACAM1 cyto (cytoplasmic 
region). They detected full length and truncated CEACAM1 as shown below (Table 17). 
Immunoprecipitation was performed using only monoclonal antibodies that detected both full 
length and truncated CEACAM1. In addition, polyclonal antibody against CEA was used for 
immunoprecipitation because it binds to most CEACAM family members. Our results 
revealed that monoclonal antibody B3 precipitated full length CEACAM1 better than the 
truncated CEACAM1 whereas it was vice versa when monoclonal antibody 4D/1C2 was 
used. Also it was observed that monoclonal antibody C5-1X was not good for 
immunoprecipitation. Therefore it was not used for immunoprecipitation in this study. 
Furthermore, we observed that in endothelial cell line AS-M.5 monoclonal antibody 4D1/C2 
detected broad bands of truncated CEACAM1 and weak bands of full length CEACAM1 
whereas, C5-1X detected broad bands of full length CEACAM1 and faint bands of truncated 
CEACAM1 although both monoclonal antibodies were not CEACAM1 N-domain binding. This 
was also observed in A549 epithelial cell. These differences may be due to the antibodies 
affinities or accessibility of their distinct epitopes domains. Therefore, our results clearly 
demonstrated that it is better to use C5-1X for detection of full length CEACAM1 and 4D1/C2 
for detection of truncated CEACAM1 variant. 
Interestingly, it was also noted that degylcosylation of CEACAM1 led to drastic reduction of 
the affinity by the detecting monoclonal antibody. This suggest that sugars are functional 
important for the binding of the antibody. 
 
Monoclonal antibodies Full length CEACAM1 Truncated CEACAM1 
18/20 Yes No 
R+D Yes No 
4D1/C2 Yes Yes 
C5-X1 Yes Yes 
B3 Yes Yes 
8G5 Yes No 
Anti-CEACAM1 (cyto) Yes No 
 
Table 17 Binding of monoclonal antibodies to full length and truncated CEACAM1. 
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6. Summary 
Previous studies have reported the presence of soluble CEACAM1 in serum, bile, saliva and 
seminal fluid, but its presence in urine was neglected (Draberova et al., 2000; Svenberg, 
1976b). Nonetheless, CEACAM1 was detected most recently in urine of healthy donors and 
its concentration was even higher in patients suffering bladder cancer (Tilki et al., 2009). 
However, until now CEACAM1 in urine was not sufficiently characterized. Therefore, the 
analysis of the doctoral thesis presented here focused on the detailed characterization of 
CEACAM1 found in urine and the determination of its origin. Furthermore, we wanted to 
understand the cause leading to the CEACAM1 secretion and the mechanism behind.  
 
CEACAM1 is a highly glycosylated cell adhesion receptor molecule. It is expressed on 
hematopoietic cells, most epithelia and angiogenicly activated endothelia. CEACAM1 plays 
an important role in cell morphogenesis, tumorigenesis, insulin metabolism, T-cell regulation 
and as a pathogen receptor. It is a member of the immunoglobulin superfamily and consists 
of one N-terminal V-like Ig domain, followed by two to three C2-like Ig domains [CEACAM1-4 
(N-A1-B-A2); CEACAM1-3 (N-A1-B)]. In most cases the CEACAM1-4 splice variants are 
expressed. Depending on the glycosylation status of CEACAM1-4 the molecular weight 
ranges from 120 kDa to 160 kDa. Beside the transmembrane-bound form soluble full length 
CEACAM1 variants have been reported. 
Our studies revealed that a high amount of CEACAM1 is present in the urine of healthy 
adults. Interestingly, with 72 kDa its molecular weight differed extensively compared to the 
known size of CEACAM1 at 120 kDa. To investigate the reason for this molecular weight 
reduction we established various sets of sandwich ELISA-systems, which enabled us to 
distinguish between the N-terminal domain, the A1B1 domain, the A2, domain and 
cytoplasmic domain, respectively. Our results showed that this novel CEACAM1 variant 
found in urine does not contain the N-domain, part of the A2 domain and cytoplasmic tail. 
Therefore, CEACAM1 in urine represents a so far unknown, truncated variant consisting of 
the A1, B and a part of the A2 domains. This finding was confirmed by Western blot analysis. 
Calculating the theoretical molecular weight of a CEACAM1 variant consiting of A1-B-part A2 
very well agrees with the CEACAM1 version found in the urine.  
As putative source of the truncated CEACAM1 we identified that cells expressing CEACAM1 
endogenously (A549, T102/3, HT29,) and those transfected with CEACAM1 (Hela-
CEACAM1) contained the native as well as the truncated form of CEACAM1. Interestingly, 
studies using cortex endothelial cell line (AS-M.5) revealed a CEACAM1 form with a 
significantly higher molecular weight of 95 kDa. However, domain mapping and 
deglycosylation studies revealed that the 95 kDa CEACAM1 variant found in endothelia 
concurred to the degylcosylated truncated CEACAM1 variant found in epithelial cells. Hence, 
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the molecular weight differences occurred just due to differences in the glycosylation level. 
Notably, no expression of truncated CEACAM1 was observed in granulocytes. 
Further studies analyzing the generation of the truncated CEACAM1 variant showed that it 
appeared neither due to differences in deglycosylation nor its production induced by 
apoptosis. Furthermore, studies utilizing A549 epithelia cells, a cell type loosing its entire 
endogenous CEACAM1 expression by entering the proliferative stage, revealed that 
truncated CEACAM1 becomes not generated when full length CEACAM1 expression is 
down-regulated in epithelial cells entering cell proliferation.  
Interestingly, our results showed for the first time that truncated CEACAM1 appeared in 
contact-inhibited cells. Extensive studies revealed that when cells were kept in the contact 
inhibited state a significant accumulation of truncated CEACAM1 appeared in the cell lysates 
and in the supernatant. 
In summary, here we demonstrate for the first time a novel truncated form of CEACAM1 in 
human urine, which does not contain the N-domain, part of the A2 domain and cytoplasmic 
tail. The present data suggest that truncated CEACAM1 is generated during molecular 
turnover processes in epithelial and endothelial cells. Thus, this study leads to a better 
understanding of CEACAM1 turnover processes and the mechanism involved. Furthermore, 
this process might serve as a mechanism resulting in the production of functionally, an 
inactive CEACAM1 form since this truncated CEACAM1 lacks the ligand binding N-domain 
and the signal transducing cytoplasmic domain. Similar turnover processes and mechanism 
involved may be applicable to other adhesion receptors such as cadherins, selectins, and 
integrins. 
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